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Abstract 
Background 
Spontaneous reporting of adverse drug reactions (ADRs) is a method of monitoring the safety of 
drugs post-marketing, providing a way to discover new, rare or unnoticed ADRs. Despite its 
importance, there is widespread underreporting of ADRs by health care professionals in South 
Africa.  
Objectives  
The study assessed the knowledge, attitudes and practices (KAP) of health care professionals 
on ADR reporting at a public hospital.   
Methods 
The questionnaire consisted of 21 questions (5 demographics; 7 knowledge; 1 attitude; 7 
practices of the participant). Hard copies of the questionnaire were completed by doctors, 
nurses and pharmacists. The results were captured on Microsoft Excel™, and imported onto 
Stata® 14 to conduct Pearson chi-squared and Fishers tests.  
Results 
297 health care professionals (87.87%) responded to the questionnaire. 50.17% had knowledge 
of reporting, and pharmacists were the most likely professionals to know how to report (82.61%) 
(p< 0.001). 96.88% of participants who had previously received ADR training knew how to 
report ADRs. 90.24% stated they would report an ADR based on the seriousness of the 
reaction. Lack of knowledge; managing the patient being more important than reporting; and 
reporting being time-consuming were some discouraging factors. 58.59% of participants had 
encountered an ADR before but only 16.50% had reported (p< 0.001).  
Conclusions  
Doctors, nurses and pharmacists were aware of the presence of ADRs, but were unlikely to 
report them. Health care professionals should be made aware of the benefits of reporting, and 
perhaps a culture of reporting can be adopted given an awareness of pharmacovigilance.  
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Introduction 
The safety, efficacy and quality of medicines are essential aspects to consider when dealing 
with the wellbeing of patients. While medicines are intended to heal, treat and prevent ailments, 
there is no certainty that they won’t themselves cause harm. When determining the safety of 
new pharmaceuticals, testing and clinical trials are conducted. These allow for a range of 
adverse drug reactions (ADRs) to be identified, some of which may show up frequently, and 
others that may be extremely rare. These ADRs are defined as the “response to a drug which is 
noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modifications of physiological function”1.  
Randomized controlled clinical trials have limits on the amount of time the drug is tested and the 
patients on which the drug; inevitably it cannot be tested on every genetic and ethnic makeup2,3. 
Post-marketing monitoring is an important feature of pharmacovigilance (PV) as it provides a 
means by which rare and population specific ADRs can be identified. PV is defined as the 
“science and activities relating to the detection, assessment, understanding and prevention of 
adverse effects or any other drug-related problem”4. 
 
Thalidomide is synonymous with PV as it brought attention to the subject of drug safety. In the 
1950’s, Thalidomide was put on the market and prescribed to pregnant women after it was said 
to be “virtually free from side effects”5. However, after taking Thalidomide, thousands of 
expectant mothers devastatingly gave birth to babies with a congenital defect called 
phocomelia, in which babies are born with underdeveloped limbs6,7,8. Following the tragedy, at 
the Sixteenth World Health Assembly in 1963, the early stages of the World Health Organisation 
(WHO) Programme for International Drug Monitoring, was proposed9. In 1978, all operational 
responsibilities were directed through the Uppsala Monitoring Centre (UMC), which holds an 
international database of ADRs, and plays a prominent role in signal detection and safety 
research10. Beginning with 10 founding members (Australia, Canada, Czechoslovakia, Federal 
Republic of Germany, Ireland, Netherlands, New Zealand, Sweden, United Kingdom, and the 
United States of America), there are currently 127 full members who have functional 
pharmacovigilance systems and meet the minimum requirements of the organization, as laid out 
by the WHO10.  
 
In 1992, South Africa met these requirements and became the first African member of the 
collective. South Africa’s PV activities have been directed by The Medicines Control Council 
(MCC), which was the “statutory body” responsible for national safety and quality of 
medicines11. A new regularity authority- The South African Health Products Regulatory Authority 
(SAHPRA) was established in 2017 to supersede the MCC.  
 
The MCC established The National Adverse Drug Event Monitoring Centre (NADEMC), to 
bridge the gap between UMC and the MCC11, and it is responsible for the collation of data from 
received ADR reports, and the “assessment of causality and risk of ADRs”12.  
 
Separately, South Africa’s National Department of Health established a National 
Pharmacovigilance Centre (NPC) in 2004, which plays an important role in collecting and 
collating programmatic reports, i.e. those relating to public health programs including TB and 
HIV13.  
 
The NPC acting in communication with SAHPRA (or the MCC previously) and the UMC 
potentially allows for the data to be fed centrally, a vital part of the system of PV in any country.  
 
			 4 
A study conducted by Ampadu et al. found that in 2015 the African continent was responsible 
for 0.88% of the global number of reports- a fraction of the rest of the world. In 2015, 28,609 
Individual Case Safety Reports (ICSRs) were submitted by South Africa, representing 0.24% of 
the total global reports14. Data is often not fed to a national system, which is evident from fewer 
generated reports12. There is a lack of collaboration between sectors, particularly the 
pharmaceutical industry, which leads to a “national database that does not include data from all 
sources”15. Olsson, Pal & Dodoo conducted a review of PV in resource limited countries and 
described that due to the shortage of health care workers in low to middle income countries, the 
perception is that it’s more important to focus on clinically managing the patient than filling out 
the paperwork involved in spontaneous reporting16. Spontaneous reporting refers to the passive 
reporting of ADRs by health care professionals or patients as they witness them17. The 
effectiveness of this voluntary type of reporting relies on the practitioner noticing an event and 
reporting it appropriately18.   
In the South African public sector, spontaneous reports are documented using the ‘Adverse 
Drug Reaction and Quality Problem Report Form’. The forms are sent to the hospital or district 
PTC, where the data is consolidated and forwarded to the secretariat of the Safety and Quality 
Subcommittee, the provincial PTC’s, the NADEMC and finally the MCC19. The reporting health 
care professional should be informed of progress and final outcomes in order to ensure an 
effective feedback cycle19. Strengthening pharmacovigilance has to include a focus on the 
importance of collaboration through continuous training12.   
Spontaneous underreporting of ADRs is a problem globally, and particularly in South Africa. 
This underreporting leads to incomplete data and can lead to trends in ADRs that go un-noticed. 
Health care professionals have a duty to report the ADRs they encounter. In order to 
understand the reasons for underreporting in the public sector, the knowledge, attitudes and 
practices of health care workers should be assessed.  
The aim of this study was to evaluate the knowledge, attitudes and practices of healthcare 
workers in the public sector towards adverse drug reaction reporting.  
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Methods 
 
Study Design 
This study was a longitudinal, questionnaire-based study. A literature review was conducted to 
gain background knowledge on the perceptions of healthcare workers on ADR reporting 
globally. A questionnaire was then compiled based on similar studies20, 21, 22. The questions 
were categorised as follows: 5 questions pertaining to demographics; 7 questions on the 
awareness of ADR reporting; 7 questions about the professional’s previous ADR reporting 
involvement; 1 question pertaining to the professional’s general attitude towards ADR reporting 
and 1 question about possible future improvements that could be made. After a pilot study using 
a group of randomly selected pharmacists, the questions were adapted appropriately. 
 Site Selection 
A public tertiary hospital in Johannesburg, South Africa was chosen. The hospital employs more 
than 4000 staff and is one of the largest teaching hospitals, serving a population of 
approximately 8 723 786 (in 2015). Based on a sample size calculation using the number of 
doctors (623), nurses (2165) and pharmacists (26) employed at the hospital (total= 2814), 338 
was found to be the appropriate number of participants. Participants were made up of 
pharmacists, nurses and medical doctors who practiced within the main hospital pharmacy and 
the ten highest volume inpatient wards (i.e. Pulmonology; Oncology; ICU (neonatal and adults); 
Surgical; Orthopaedic; Renal; Gynaecology; Diabetes; Gastroenterology; Cardiac).  
 Data Collection  
Participation in the questionnaire occurred over the period between July and November 2016, in 
which the hard copies of the questionnaires were disseminated and collected. The 
questionnaires were distributed to pharmacists, and to head nurses at wards, who distributed 
and collected the questionnaires within their departments. Participants were required to 
complete the informed consent form and were given appropriate instructions for filling out the 
questionnaire.  
 Data Analysis 
Data was collected in the form of the hard copy questionnaire responses from pharmacists, 
doctors and nurses. The data was then electronically captured on to spreadsheets on Microsoft 
Excel™. The questionnaire responses was categorized in terms of: the demographics of the 
person participating; the current awareness of the participant (i.e. knowledge); the attitude of the 
professional towards PV; any prior PV involvement the participant may have had (i.e. practices); 
and the need for further PV training or other suggestions. The data captured on Microsoft 
Excel™ spreadsheets was imported on Stata® (Version 14). Pearson chi squared and Fishers 
tests were run in order to discover significant associations in the data.  
Ethical Considerations  
Ethics approval was granted by the University of the Witwatersrand Human Research Ethics 
Committee (HREC) (No. M160246). 
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Results 
 
Demographics  
Two hundred and ninety-seven questionnaires were returned out of the sample size calculated 
of 338, to yield a 87.87% response rate. The respondents were made up of 41 doctors; 230 
nurses; 24 pharmacists and 2 participants did not indicate their profession. Forty-nine percent of 
participants were qualified professionals having already completed their internships and 
community service. The majority (83.84%) of participants were female.  
 Knowledge of the Participants  
Table 1 shows  the knowledge of the participants. Over 50% of participants stated they knew 
how to report an ADR, and 77.10% stated that they were familiar with the form. Participants 
chose many reasons for the importance of ADRs, with most participants checking all the options 
for that question. 
Table 2 shows the knowledge of the participants by profession. Fifty-four percent of the nurses 
stated they didn’t know how to report, while 53.59% of doctors and 82.61% of pharmacists know 
how to report.  
In terms of the level of practice, more than half of the participants (53.77%) who knew how to 
report had been practicing as health care professionals for 6-10 years. Participants who were 
newest to practicing (<1 year) had little knowledge of reporting with 76.47% of participants 
stating they didn’t know how to report. Fifty-eight percent of post-community service participants 
knew how to report ADRs, whereas only 23.08% of interns knew how to report ADRs.  
Attitudes of the Participants  
Table 3 shows the frequency distribution of the results pertaining to the attitudes of the 
participants towards PV. Over ninety percent of the participants (90.24%) stated they would 
report an ADR based on the seriousness of the reaction. Various factors such as not knowing 
how to report; not knowing where to report; managing the patient being more important than 
reporting; and reporting being time-consuming, made up most of the factors that discouraged 
participants from reporting. Figure 1 shows participant’s opinions on which health profession 
should be held responsible for reporting ADRs. Ninety-three percent of participants felt medical 
practitioners should be held responsible, followed by 88.89% for nurses and 76.77% for 
pharmacists. Two percent of participants chose “other” which was made up of the response 
“patients”.  
Practices of the Participants  
Table 4 shows previous PV activity in which participants may have been involved, of which only 
10.77% of participants had received previous PV training. Of the 58.59% of participants who 
encountered an ADR in practice, only 16.50% reported the encountered ADR. The vast majority 
of participants (73.74%) submitted <1 ADR per year.  
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Discussion  
Knowledge of Health Care Professions On ADR Reporting 
Participants in this study had some awareness of pharmacovigilance, side effects and adverse 
drug reactions. Health care professionals have demonstrated a relative awareness for the 
presence of ADRs in studies similar to this one, including that of Fadare et al.23, and 
Pimpalkhute et al.21. However, these studies also found a lack of awareness of the process of 
reporting. Fadare found that although 93.8% of participants had knowledge of reasons to report 
ADRs, only 39.5% of participants were aware of the actual reporting form23. Similarly, according 
to Suyagh, Farah and Farha, only 28.6% of hospital pharmacists were aware of the reporting 
system in Jordan22. In this current study, the questionnaire results showed that 50.17% of 
participants knew how to report ADRs, and 77.10% were aware of the yellow reporting form.  
In terms of knowledge of the pharmacovigilance reporting system, 59.26% of participants 
identified NADEMC as the place to report ADRs, while only 48.82% chose the PTC as an 
option. Fadare et al. found a similar figure (44.6%) of participants who were aware of the 
existing hospital committee23. Although the NADEMC is the national monitoring centre, the PTC 
should also be recognised as an important channel for communication within the institution. 
Provincial PTCs play a significant role in the collection of ADR reports. Ideally, the gathering of 
reports for provincial PTCs is a function that happens through the Safety and Quality 
Subcommittee, which physically gathers and collates the data, looking for potential concerning 
trends. Communication and integration among all health care professionals may help to give 
holistic care, and in many ways can make the involved persons more motivated.  
The study found different levels of knowledge among the different professions. Nurses had the 
least knowledge of how to report (46.46%) , followed by doctors (53.49%) and then pharmacists 
(82.61%) (p< 0.001). De Angelis et al. concluded that “Nurses are not fully aware of their role in 
adverse drug reaction reporting”24, and Hanafi et al. had a similar finding with 89% of nurses 
preferring to refer the report to the doctor for completion25. 
Health care professional’s knowledge of the flow of reporting as well as their awareness of who 
should take responsibility of reporting need to be enforced. This brings up the need to train 
heath care professionals more constantly, through the use of in-service training and more 
formalised classroom-based learning at the undergraduate level. This study also found a 
statistical association between knowledge of ADR reporting and the years of experience of 
participants. Participants who are newer to practicing as health care professionals seemed to 
have knowledge of the importance of reporting, however there is a lack of knowledge of the 
process itself (p-value = 0.000). Only 23.08% of interns knew how to report ADRs, yet 61.45% 
had seen the reporting form before (p< 0.001). These findings were consistent with that of 
Elkami et al. who found that deficiencies in the undergraduate curriculum lead to a lack of 
knowledge about pharmacovigilance26.  
Attitudes Of Health Care Professionals On ADR Reporting 
Attitudes in this study were measured by the factors that encouraged and discouraged health 
care workers, as well as the cases in which they were most likely to report ADRs. These factors 
accounted for some of the gaps between knowledge and practice. Believing that ADR reporting 
is important is an inevitable start to reporting ADRs, and this study found that only 21.89% of 
participants chose “did not think it was important to report” as a reason for underreporting. 
Similarly, Gupta and Udapa found that 89.5% of doctors thought reporting was an important part 
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of their profession27, and Joubert and Naidoo found that 79.4% of participants “regarded PV as 
a valuable tool”17.  
A range of factors discouraged participants from reporting, with “managing the patient was more 
important than reporting”, “do not know how to report”, and “do not know where to report” being 
the most frequently answered. “Ignorance about the reporting system” found in this study was 
consistent with the results of Desai et al20. Most health care professionals cited the seriousness 
of the ADR (90.24%) as the main encouraging factor in deciding whether to report an ADR, 
comparable to the 88.9% found by Gupta and Udapa27.  
Practices of Health Care Professionals on ADR Reporting 
The practices of health care professionals were assessed through responses based on 
encountered ADRs versus reported ADRs. 58.59% of participants had encountered an ADR in 
practice, yet only 16.50% reported the encountered ADR (p<0.001). Fadare et al. discovered 
that although more than 80% of participants had previously witnessed an ADR, 42.7% chose 
not to report it23.   
Vallano et al. found the availability of reporting forms to be a major barrier of reporting29. In this 
study, although 59.26% of participants stated the forms were easily available to them in 
practice. This issue is one that should be addressed at each institution and brings up the need 
for heads of department to play a role in integrating pharmacovigilance into the topics discussed 
at routine meetings.  
Suggestions and Future Recommendations 
Education should remain a priority in the field of pharmacovigilance, and the idea of training was 
a fundamental point of discussion during focus group sessions. Over 96% of participants who 
had previously attended a training seminar stated they knew how to report ADRs. Similarly, De 
Angelis et al24; Lopez-Gonzalez30; Backstrom et al.31; Sevene et al.32; and Cereza et al.33 found 
increases in reports after training, and higher rates of reports from health care professionals 
with a higher level of education. Sevene et al.32; and Kaselekela Oscar & Boyd34 focused on 
pharmacovigilance in resource-limited countries, and mentioned continuous training, public 
awareness and the importance of feedback in reporting ADRs.   
Training should be consistent starting from the undergraduate level and continuing into routine 
training sessions in the workplace35, 36.Pimpalkhute noticed gaps in “undergraduate training” 
(2012, p. 60), while Olsson, Pal and Dodoo noted the importance of introducing PV training into 
undergraduate studies21. An approach targeted at students saw a “student- run 
pharmacovigilance programme” being piloted in the Netherlands37. This ideas allows for 
students to learn in a more practical way the importance of PV, which they can then carry into 
their professions.  
Post-graduation, there is a need to renew the skills of PV. A possible idea for this, while also 
utilising the idea of incentives, is the allotment of Continuous Development Points (CPDs) to 
reporting healthcare workers. A study conducted in India found positive results following the 
implementation of this idea. Sixty-seven percent of healthcare workers had no awareness of 
ADR reporting prior to the study, but results showed an increased rate of reporting after the 
program was introduced38. Similarly, an idea implemented in the UK in the form of “e-learning 
modules” allows healthcare professionals to familiarise themselves with ADR reporting39. This 
allows for a continuous platform for training on ADRs, as well as the added incentive of 
receiving CPD credits.   
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Health care professionals also want to be kept up to date and involved, and so PV bulletins and 
meetings may be of great use once the culture of reporting is established.  
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Tables and Figures  
 
Table 1: Frequency Distribution of Participants Knowledge of PV (N=297) 
Responses  Frequency (%) Percentage (%) 
Knowing how to report an ADR 
Yes 149 50.17 
No  145 48.82 
Total 294 (*=3)   
Familiar with the reporting form 
Yes 229 77.10 
No  65 21.89 
Total  294 (*=3)   
Where to report ADRs 
The National Adverse Event Monitoring Centre (NADEMC) 176 59.26 
Pharmaceutical and Therapeutics Committee (PTC) 145 48.82 
The Medicines Control Council (MCC) 143 48.15 
Medical Supply Depot (MSD) 38 12.79 
The Safety and Quality Subcommittee  70 23.57 
Other  12 4.04 
"Doctor and Pharmacy in Hospital" 3   
"Pharmaceutical Company" 1   
"The Drug Controller" 2   
"Supplier"     
Total  584   
Why it’s important to report ADRs 
To identify new ADRs 1375 92.59 
To improve patient safety 1401 94.34 
To measure the incidence of ADRs 1376 92.66 
To share information about ADRs with colleagues 1347 90.71 
To identify relatively safe drugs 1357 91.38 
			 16 
It is a requirement 1315 88.55 
 
Table 2: Knowledge of How to Report ADRs by Profession (N=292) 
 Profession of Participant 
Response Doctor Nurse Pharmacist All 
Yes 23  
(53.49%) 
(15.65%) 
105  
(46.46%) 
(71.43%) 
19  
(82.61%) 
(12.93%) 
147  
(50.34%) 
(100%) 
No 18  
(41.86%) 
(12.59%) 
121  
(53.54 %) 
(84.62%) 
4  
(17.39%) 
(2.80%) 
143  
(48.97%) 
(100%) 
Invalid Response 2  
(4.65 %) 
(100%) 
0  
(0.00%) 
(0%) 
0  
(0.00%) 
(0%) 
2  
(0.68%) 
(100%) 
Total  43  
(100%) 
(14.73%) 
226  
(100%) 
(77.40%) 
23  
(100%) 
(7.88%) 
292  
(100%) 
(100%) 
Pearson Chi-square =  23.1900,   p-value = 0.000, Fisher's exact for scores <5 = 0.000 
(p<0.001)  
 
Table 3: Frequency Distribution of Participant's Attitudes (N=297) 
Response Frequency (N) Percentage (%) 
Cases most likely to report ADR 
Seriousness of the ADR 268 90.24 
Unusualness of the reaction 160 53.87 
Involvement of a new drug  139 46.80 
Level of certainty that it is an ADR 85 28.62 
None of the above  2 0.67 
Total  654  
Factors discouraging participants from reporting ADRs 
			 17 
Do not know how to report 97 32.66 
Not knowing where to report 96 32.32 
Did not think it was important to report  65 21.89 
Managing the patient was more important than reporting ADRs 115 38.72 
Lack of access to ADR reporting form 49 16.50 
Patient confidentiality  46 15.49 
It is time-consuming  95 31.99 
There is a lack of feedback after forms have been submitted  65 21.89 
Other 7 2.36 
"Inexperience" 1  
"No discouraging factors" 2  
Total  635  
ADRs that should be reported 
None 1 0.34 
All ADRs  182 61.28 
All serious ADRs 132 44.44 
ADRs to new drugs 59 19.87 
Unknown ADRs to old drugs 47 15.82 
ADRs to herbal and non-allopathic drugs  23 7.74 
ADRs to vaccinations 28 9.43 
Other 3 1.01 
Total  475  
Professionals who should report ADRs 
Medical practitioners 275 92.59 
Nurses 264 88.89 
Pharmacists 228 76.77 
Other 7 2.36 
"Patient" 2  
Total  774  
Reference materials participants would use 
Textbook 177 59.60 
			 18 
Colleague 211 71.04 
Internet 236 79.46 
Package Insert 224 75.42 
Other 3 1.01 
Total  851  
*= missing data  
 
Figure 1: Perceived Responsibility for Reporting ADRs 
Table 4: Frequency Distribution of Previous PV Activity (N=294) 
Response Frequency (N) Percentage (%) 
Any previous training seminars/workshops on ADR reporting? 
Yes  32 10.77 
No  262 88.22 
Total  294 (* =3)  
Are ADR reporting forms easily available to you in practice? 
Yes  176 59.26 
No  93 31.31 
Total  269 (* =28)  
Have you ever encountered an ADR in practice? 
Yes  174 58.59 
92.59 88.89
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No  115 38.72 
Total  289 (* =8)  
Have you ever reported an ADR that you encountered? 
Yes  49 16.50 
No  238 80.13 
Total  287 (* =10)  
How many ADR reports have you submitted on average? 
<1/ year 219 73.74 
1-10/ year 23 7.74 
<1/month 5 1.68 
1-10/ month 2 0.67 
Total  249 (* =48)  
*= missing data  
Table 5: Participants who Encountered ADRs versus those that Reported the Encountered ADR 
(N=285) 
 Reported an Encountered ADR  
Encountered an ADR Yes No  Total  
Yes 47                     
(27.17%)               
(95.92%) 
126                          
(72.83%)               
(53.39%) 
173                      
(100%)            
(60.70%) 
No  2                           
(1.79%)               
(4.08%) 
110                      
(98.21%)              
(46.61%) 
112                         
(100%)            
(39.30%) 
Total  49                         
(17.19%)             
(100%) 
236                       
(82.81%)             
(100%) 
285                                          
(100%)                  
(100%) 
Pearson Chi-square= 30.7645, p-value= 0.000 (p<0.001) 
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ABSTRACT  
 
Introduction and Objectives  
Spontaneous reporting of adverse drug reactions (ADRs) is a method of monitoring the safety of 
drugs post-marketing, providing a way to discover new, rare or unnoticed ADRs. Despite the 
importance of this, there is widespread underreporting of ADRs by health care professionals in 
South Africa. This study was used to assess the knowledge, attitudes and practices (KAP) of 
health care professionals on ADR reporting at a public tertiary hospital as a way to evaluate 
reasons for underreporting and suggestions for future improvement.  
Materials and Methods  
The study was conducted at 10 wards and the pharmacy. The baseline assessment consisted of a 
questionnaire of 21 questions (5 demographics; 7 knowledge; 1 attitude; and 7 pertaining to 
practices of the participant). Hard copies of the questionnaire were provided and completed by 
doctors, nurses and pharmacists. The results were captured on Microsoft Excel™ spreadsheets, 
and then imported onto Stata® 14 to conduct Pearson chi-squared and Fishers tests. Following 
this, 4 focus group sessions were conducted with nurses and pharmacists in order to assess 
reasons for under-reporting and thoughts and opinions on how to improve the system of 
reporting at CMJAH.  
Results  
A total of 297 health care professionals (87.87%) responded to the questionnaire, the majority of 
which were nurses (77.44%). 50.17% said they knew how to report an ADR, and pharmacists 
were the most likely professionals to know how to report ADRs (82.61%) (p< 0.001), but 
explained a lack of reporting due to time-constraints during daily practice. 96.88% of 
participants who had previously received ADR training knew how to report ADRs. 90.24% of 
participants stated they would report an ADR based on the seriousness of the reaction. Lack of 
knowledge; managing the patient being more important than reporting; and reporting being time-
consuming were listed as discouraging factors. 58.59% of participants had encountered an ADR 
before but only 16.50% had reported (p< 0.001). Training and education was noted as the 
primary way to improve the reporting rate, but it was also suggested that one person be put in 
charge of pharmacovigilance in each department, in order to manage time-related issues.   
Conclusions  
Doctors, nurses and pharmacists were aware of the presence of ADRs, but were unlikely to 
report them mostly due to a lack of training. Health care professionals need to be made more 
aware of the benefits of reporting, and perhaps a culture of reporting can be adopted given an 
awareness of PV.  
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CHAPTER I: INTRODUCTION 	
Rational use of medicines has become an important topic of focus within the health science 
industry, with access to medicines and medical knowledge continuing to improve into the 21st 
century. The need to provide safe and effective medicines remains essential, and the role of 
health care professionals in safeguarding the use of medicines should remain a priority. Side 
effects, defined as “any unintended outcome that seems to be associated with treatment, 
including negative or positive effects” (UMC, 2017), are inevitable consequences to the use of 
medicines. Adverse effects can lead to life threatening ailments in more serious cases. The World 
Health Organization (WHO) defines an adverse drug reaction (ADR) as “a response to a drug 
which is noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function” 
(WHO, 1972). 		
The registration of medicines is a rigorous process and medicines go through various phases of 
clinical trials in which many of the risks of taking the drug are evaluated and become recognized. 
However, due to the limitations that exist within these controlled clinical trials, including the 
limited amount of time allocated to testing (Wiktorowicz Lexchin & Moscou, 2012), some 
effects may go un-noticed, especially those that only become present after an extended time 
period. Once on the market, drugs tested on certain patient populations will inevitably be used by 
a wider variety of people with differences in genetics and ethnicity (Eliasson, 2006). Therefore, 
it is vital that measures be put in place to monitor patients post-marketing. Post marketing 
surveillance provides a means by which rare and population specific ADRs can be identified.  
The impact of ADRs on health can be devastating, especially when they are not identified 
timeously. Polypharmacy (taking an assortment of drugs concurrently) often leads to a situation 
where it is not clear what the causative agent of a given reaction may be (Nobili et al., 2011). 
The growing practice of self-medication and the lack of awareness of ADRs increases the 
likelihood that ADRs will go undetected with dire consequences. A study conducted by 
Hakkarainen et al. in 2012 discovered that 52% of the ADRs experienced by outpatients, and 
45% of ADRs experienced by hospital patients were preventable (Hakkarainen). The awareness 
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of health care professionals, as well as the empowerment of patients in noticing adverse effects, 
is not only important but potentially life-saving (Mehta, 2011).  
Together with the harm caused to a patient’s health by a drug intended for treatment, ADRs also 
manifest themselves as a substantial economic burden. In one German study, it was found that 
treating an ADR cost an average of 382 Euros per ADR and 58% of these total costs lead to 
hospitalization (Stark, John & Leidl, 2011). A cross sectional study performed in four South 
African hospitals found 8.4% of hospital admissions to be ADR related (Mouton et al., 2016). 
The costs incurred from hospital admission; prolonged hospitalization and any further therapy 
that may be required can add significantly to patient costs and discomfort.  
The reporting of ADRs allows for a way to monitor the safety of medicines and enable global 
awareness of the potential harms of certain drugs. A study conducted by Onakpoya, Heneghan & 
Aronson reviewed market withdrawals that occurred between 1950 and 2013, and discovered 
that 95 drugs were withdrawn as a result of death (2015). A subsequent study found 462 drugs 
withdrawn from the market as a result of an adverse drug reaction (Onakpoya, Heneghan & 
Aronson, 2016). Post-marketing surveillance in the form of ADR reporting acts in an effort to 
avoid delayed action in ensuring safety of drugs on the market. Through the implementation and 
adherence to a pharmacovigilance system, potential risks to patient health can be detected, and 
medicines not deemed safe enough for use can be removed. Pharmacovigilance is defined as the 
“science and activities relating to the detection, assessment, understanding and prevention of 
adverse effects or any other drug-related problem” (WHO, 2010, p.1). The WHO defines a 
Pharmacovigilance Reporting System as: “the core data-generating system of 
pharmacovigilance, relying on healthcare professionals and patients to identify and report any 
suspected adverse effects from medicines to their local or national pharmacovigilance centre or 
to the manufacturer” (UMC, 2017, n.p) and this gives way to a method of monitoring potential 
health risks.  
Adherence to a Pharmacovigilance Reporting System differs between countries, often based on 
income and thus, resources. A study exploring the patterns of reporting ADRs found that 
reporting rates are higher in high income countries than they are in low income countries. 
(Aagard, 2012). The same study found South Africa to have a reporting rate of 11, compared to 
that of the United Kingdom with 233 (reports/million inhabitants/ year). Within a health care 
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setting like the one in South Africa, the public sector often lacks the necessary resources and 
infrastructure that enables higher income countries to gather data efficiently. In recent years, 
global funding has also increased access to medicines in developing countries. This has caused a 
further need for the proper training and education of health care professionals in these countries, 
who may have had little focus on PV in the past (Olsson et al., 2015).  
It is essential for healthcare workers to assume responsibility for monitoring the safety of 
medicines, and it should be viewed as a professional obligation. Reasons for under-reporting 
globally have been well researched and largely relate to issues pertaining to the knowledge, 
attitudes and practices of health care professionals. The perceptions of health care workers, 
especially those in direct contact with patients, should be enhanced in order to effectively 
increase the rate and quality of reporting, possibly leading to fewer hospital admissions and 
improved patient safety.  
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CHAPTER II: LITERATURE REVIEW  	
2.1 A BRIEF HISTORY OF PHARMACOVIGILANCE  
	
Figure 2.1: Timeline of the Basic Events of Pharmacovigilance in the South African Context 	
Drug disasters throughout modern history, including the Thalidomide tragedy in the 1950’s- 
1960’s in many ways led to the development of the field of PV. Before being put on the market, 
Thalidomide underwent clinical trials and was claimed to be “virtually free from side effects” 
(Lenz, 1988, pp.1). However, expectant mothers, who took the drug, devastatingly gave birth to 
babies with a congenital defect called phocomelia, in which babies are born with underdeveloped 
limbs (Kumar, 2010; Miller, 1991; McBride, 1961). This disaster brought attention to the issue 
of medicine safety, and the need for stricter regulations globally. In an effort to proactively avert 
such drug disasters, at The Sixteenth World Health Assembly, a pilot concept was born and this 
later became known as the World Health Organisation (WHO) Programme for International 
Drug Monitoring (WHO, 2002). The concept of PV then became widely recognised, 
encompassing the following as defined by the WHO: “drug monitoring; pharmaceutical 
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preparations- adverse effects; adverse drug reaction reporting; product surveillance, post 
marketing (and) legislation” (WHO, 2002).  
The WHO Programme for International Drug Monitoring began with 10 founding members in 
1968: Australia, Canada, Czechoslovakia, Federal Republic of Germany, Ireland, Netherlands, 
New Zealand, Sweden, United Kingdom, and the United States of America, before directing all 
operational responsibilities through the Uppsala Monitoring Centre (UMC) in 1978. The Uppsala 
Monitoring Centre became the controlling body, taking on the responsibility for collecting 
reports and information on ADRs, and supporting member countries in their pharmacovigilance 
activities (UMC, 2017). Currently, the UMC holds an international database of Adverse Drug 
Reactions (ADRs), known as “Vigibase”, and plays a prominent role in signal detection and 
safety research (UMC, 2017). Signal detection is the “notice of an early concern or hypothesis 
about a possible medicines safety problem, with evidence and arguments to support it” (UMC, 
2017, n.p). It aims to discover and communicate pertinent information about the risks of 
medicines (UMC, 2017). The members of the UMC have grown in number over time and there 
are currently 127 full members and 28 associate members, who are on their way to developing a 
functional pharmacovigilance system (UMC, 2017). The UMC consolidates reporting data from 
member countries, which comply with the “minimum requirements for a functional 
pharmacovigilance system” (WHO, 2010). The following is a list of said requirements as laid out 
by WHO (2010):  
Table 2.1: Minimum Requirements for a Functional Pharmacovigilance System (WHO, 2010) 
1 A national pharmacovigilance centre with designated staff (at least one full time), stable basic funding, clear 
mandates, well defined structures and roles and collaborating with the WHO Programme for International 
Drug Monitoring.  
2 The existence of a national spontaneous reporting system with a national individual case safety report (ICSR) 
form i.e. an ADR reporting form.  
3 A national database or system for collating and managing ADR reports.  
4 A national ADR or pharmacovigilance advisory committee able to provide technical assistance on causality 
assessment, risk assessment, risk management, case investigation and, where necessary, crisis management 
including crisis communication.  
5 A clear communication strategy for routine communication and crises communication.  
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2.2 SOUTH AFRICA’S COMPLIANCE TO THE WHO MINIMUM REQUIREMENTS 
FOR A FUNCTIONAL PHARMACOVIGILANCE SYSTEM  	
	
Figure 2.2: South Africa's Compliance with WHO Minimum Requirements                                     
(Mehta, 2011; Mehta, 2014; WHO, 2010) 
South Africa met these minimum requirements and became a member country of the UMC in 
1992, before any other African country (Mehta, 2014). South Africa’s PV activities are directed 
by The Medicines Control Council (MCC), which is the “statutory body” responsible for national 
safety and quality of medicines (Mehta, 2011, p.248). The MCC amended its act (Medicines and 
Related Substances Control Act 10 of 1965) in 1997 by adding Regulations 34 (Conduct of 
Clinical Trials for Humans) and 37 (Adverse Drug Reactions) (MCC, 1997). Regulation 34 
makes provision for the application required to be completed upon desire to conduct any clinical 
trial, and the requirements to be fulfilled by potential investigators (MCC, 1997). Regulation 37 
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directly makes provisions for the holder of the registration of a medicine to timeously report 
suspected ADRs to the MCC, emphasizing the importance of ADR forms and collected data 
(MCC, 1997).  
The MCC consequently published guidelines on reporting ADRs titled: ‘Reporting Adverse 
Drug Reactions in South Africa’, outlining clearly the relevant terminology pertaining to ADRs, 
as well as the process of reporting (MCC, 2014). It also makes provision for pharmaceutical 
companies to have at least one full time employee to manage pharmacovigilance affairs, and to 
report information to the NADEMC. According to the guidelines, serious and non-serious ADR 
reports should be submitted within 15 days of a witnessed reaction, using the prescribed national 
individual case safety report (ICSR) form. In South Africa, the preferred form is the ‘Adverse 
Drug Reaction and Quality Problem Report Form’ (Appendix A), however, individual forms 
used by institutions are also accepted, as long as the relevant information is provided.  
The MCC established The National Adverse Drug Event Monitoring Centre (NADEMC), to 
bridge the gap between UMC and the MCC (Mehta, 2011), and it is responsible for the collation 
of data from received ADR reports, and the “assessment of causality and risk of ADRs” 
(Maigetter, 2010), thus fulfilling the role of managing the national database.  
South Africa’s National Department of Health (NDOH) subsequently established a National 
Pharmacovigilance Centre (NPC) in 2004, which plays an important role in collecting and 
collating programmatic reports, i.e. those relating to public health programs including TB and 
HIV (Dheda, 2016). The NPC acting in communication with the MCC and the UMC potentially 
allows for the data to be fed centrally, a vital part of the system of PV in any country.  
On a clinical level, the development of PV advisory committees, which can report to the national 
centre, allows for ease of communication and the ability to deal with issues within the hospital 
environment. It was suggested at the First International Conference on Improving Use of 
Medicines (ICIUM) that hospital committees be developed (WHO, 2003). In South Africa, these 
hospital committees are termed Pharmaceutical and Therapeutics Committees (PTC’s), and they 
deal with “problems of drug selection, procurement, distribution and use” (WHO, 2003). PTC’s 
are responsible for managing ADRs and managing medication errors, as well as “evaluating the 
clinical use of drugs” and “managing the formulary” (WHO, 2003). These forums provide a way 
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in which public sector institutions can integrate gathered information, and then report this 
information to national centres. They also serve as a potential platform for feedback on ADR 
management at a clinical level. PTC’s have proven effective in improving rational drug use when 
utilized effectively, and the WHO is committed to promoting the functioning of these 
committees in developing countries (WHO, 2003). ‘The National Policy for the Establishment 
and Functioning of Pharmaceutical and Therapeutics Committees in South Africa’ (2015) 
published by the National Department of Health outlines the goals, and policies that should be 
adhered to in order to have an effective PTC. Members of a PTC have a “range of expertise and 
skills” (National Policy, 2015, pp. 8) to provide a holistic advisory committee. The emphasis on 
communication between health care professionals is important as it allows for thorough clinical 
problem solving and thus improved patient care.   
South Africa has established the necessary framework to meet the minimum requirements. As a 
member of the UMC, South Africa is also obligated to keep the system updated and submit 
ICSRs to the UMC at least quarterly (UMC, 2017).  
Table 2.2: Summary of the Functions of PV Authorities  
WHO UMC 
 
MCC 
 
NADEMC 
 
NPC 
Responsible for 
directing PV globally 
through the WHO 
Collaborating Centre 
for International Drug 
Monitoring  
Created by the 
WHO as the 
operational body 
responsible for PV; 
holds an 
international 
database of ADRs  
The MCC is 
medicine regulatory 
authority in South 
Africa, and is 
responsible for the 
regulatory aspects of 
PV  
Established by the 
MRA to collate 
ADR reports, and 
acts in 
communication with 
UMC 
Primarily responsible 
for collating reports 
pertaining to public 
health programmes 
such as HIV and TB  
(Dheda, 2016; Mehta, 2011; WHO, 2010; UMC, 2017) 
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2.3 REPORTING RATES IN SOUTH AFRICAN VS THE REST OF THE WORLD 	
A study comparing the reporting rates of developed and developing countries showed that 
between 2000 and 2009, the USA and the UK generated an average of 40,6274 and 14,2555 
reports per year respectively. Compared with South Africa and India, which generated 5518 and 
362 reports per year respectively, significant differences between developed and developing 
countries seem to exist (Aagaard et al., 2012). An important consideration is the disease burden 
in the country, as well as the type of treatments patients use outside of western medicine such as 
traditional medicine.  In South Africa, HIV and TB account for a large patient demographic, and 
a high incidence of ADRs a result of the corresponding treatment, leading to a further need to 
monitor patients on their treatment (Mehta et al., 2008).  
A study conducted by Ampadu et al. found that in 2015 Africa as a continent was responsible for 
0.88% of the global number of reports- significantly lower than the rest of the world. In 2015, 
28,609 ICSRs were submitted by South Africa, representing 0.24% of the total global reports 
(Ampadu, 2015). The trend is that data is often not fed to a national system, which is evident 
from fewer generated reports (Maigetter et al., 2015). There is a lack of collaboration between 
sectors, particularly the pharmaceutical industry, which leads to a “national database that does 
not include data from all sources” (Ouma & Abwao, 2012, p.9). Olsson, Pal & Dodoo conducted 
a review of PV in resource limited countries and described that because there is a shortage of 
health care workers in low to middle income countries, the perception is that it’s more important 
to focus on clinically managing the patient than filling out the paperwork involved in 
spontaneous reporting (2015).  
 
2.4 TYPES OF REPORTING: SPONTANEOUS, TARGETED AND COHORT EVENT 
MONITORING 	
ADR data gathered largely consist of spontaneous reports, which has been the mainstay approach 
to ADR reporting globally for many years. Spontaneous reports refer to passive reporting of 
ADRs by health care professionals or patients as they witness them (Joubert & Naidoo, 2016). 
The effectiveness of this voluntary type of reporting relies on the practitioner noticing an event 
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and reporting it appropriately (Mulatu & Worku, 2014). Provided its framework is adhered to, 
“spontaneous reporting systems provide the highest volume of information at the lowest 
maintenance cost” (Pal et al., 2013, p.75).  
Targeted reporting is a different system of reporting, in which ADRs are noticed by monitoring 
particular groups of patients through active surveillance (Pal et al., 2013). This type of reporting 
involves the analysis of prescription data and the completion of questionnaires by health care 
practitioners, detailing all relevant information (Härmark & van Grootheest, 2012). Targeted 
reporting aims to minimize the “under-reporting” that may occur from the reliance on the 
voluntary nature of spontaneous reporting (Härmark & van Grootheest, 2012, p.10), however it 
is also a valuable tool when used in conjunction with spontaneous reporting. In response to a 
signal generated by spontaneous reports, targeted reporting could provide more specific 
information about particular groups of patients, such as those with critical illnesses (Pal et al., 
2013).  
Similarly, Cohort Event Monitoring (CME) programmes are established to monitor the safety 
and efficacy of medicines, and are based on the conduction of “prospective observational cohort” 
studies (Pal et al., 2013). In South Africa, CME has been used often in the field of ARV’s, as 
well as TB. The aim is to continuously gather patient data in order to improve the treatment 
outcomes of patients on lifelong therapy (Vusi, 2014).  
 
2.5 SPONTANEOUS REPORTING IN SOUTH AFRICA  	
In South Africa, ADR reports are documented via the ‘Adverse Drug Reaction and Quality 
Problem Report Form’ (Appendix A) - a product of the NADEMC. This form is completed with 
attention given to patient information; a full description of the reaction; details of the treatment 
including dosage and duration and details of the outcome. In the public sector, the forms are sent 
to the hospital or district PTC, where the data is consolidated and forwarded to the secretariat of 
the Safety and Quality Subcommittee, the provincial PTC’s, the NADEMC and finally the MCC 
(Guidelines for Implementation of Pharmaceutical and Therapeutics Committees in Gauteng 
Province, 2013). The reporting health care professional should be informed of progress and final 
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outcomes in order to ensure an effective feedback cycle (Guidelines for Implementation of 
Pharmaceutical and Therapeutics Committees in Gauteng Province, 2013). However, the 
information between channels is often not fed back, which may lead to a lack of available data, 
as well as demotivated health care workers. Strengthening pharmacovigilance has to include a 
focus on the importance of collaboration through continuous training (Maigetter, et al., 2015).  
	
2.6 KNOWLEDGE, ATTITUDE AND PRACTICES OF HEALTH CARE 
PROFESSIONALS  	
A standard of reporting can be adhered to given the right attitudes and knowledge of health care 
practitioners, who have a duty to adopt a “culture of reporting” when monitoring patients during 
their treatment process (Pimpalkhute et al., 2012, p.56). How much information is gathered and 
duly reported largely depends on the awareness and assertiveness of the professional 
(Pimpalkhute et al., 2012). The reasons for the underreporting of ADRs by health care 
professionals have been researched globally. Isah et al. list the following reasons for 
underreporting in Africa: “inability to recognize ADRs, ignorance of the reporting requirements, 
lack of reporting forms, feeling of guilt following the occurrence of adverse effects and fear of 
litigation” (2011). These factors cause health care professionals to not adhere fully to the 
framework of reporting, which leads to inadequate or incomplete data.  
ADRs can lead to serious and even fatal consequences, shown by the “high prevalence of 
hospital admissions” worldwide (Suyagh, Farah & Farha, 2014, p.147-148). The future of 
medicine safety cannot be improved if ADRs are not adequately reported (Fadare et al., 2011). It 
is vital that the approach to PV is one that collaborates efforts from “drug regulatory authorities, 
pharmaceutical industry and all healthcare providers” (Kshirsagar, Olsson & Ferner, 2010, p.65). 
In the future, education and training for all involved parties can possibly enhance the reporting 
rate and the quality of reporting in developing countries (Elkami et al., 2011). Particularly in 
South Africa, it is evident that healthcare workers need more education and a better 
understanding of the frameworks (Mehta, 2011). Providing knowledge on the importance of 
ADRs and its impact on downstream costs, time spent, and the overall livelihood of the patient 
may be the catalyst to improving reporting habits.  
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2.7 AIM OF THE STUDY  
 
The aim of this study was to determine the knowledge, attitudes and practices of pharmacists, 
doctors and nurses at a tertiary hospital.  
 
2.8 RESEARCH OBJECTIVES 	
• To assess the current levels of knowledge of doctors, nurses and pharmacists on ADR 
reporting.  
• To assess the attitudes of doctors, nurses and pharmacists towards ADR reporting. 
• To assess the practices of doctors, nurses and pharmacists with regards to ADR reporting. 
• To identify trends and relationships between knowledge, attitudes and practices on ADR 
reporting. 
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CHAPTER III: METHODOLOGY  	
3.1 SELECTION OF INSTITUTION   	
The study was conducted at a public tertiary hospital, which is a teaching hospital in the Gauteng 
Province. The hospital employs more than 4000 staff and serves a population of approximately 
8 723 786, along with another large teaching hospital in the area. The institution was chosen to 
conduct the study within the main hospital pharmacy, and inpatient wards, chosen based on the 
trends of inpatient volume from 2015. The ten wards with the highest inpatient intake in 2015 
were Pulmonology; Oncology; ICU (neonatal and adults); Surgical; Orthopaedic; Renal; 
Gynaecology; Diabetes; Gastroenterology; and Cardiac.  
3.2 STUDY DESIGN  	
The study is a longitudinal, sequential explanatory study, a type of mixed-methods study 
beginning with a quantitative aspect (i.e. questionnaire), followed by a qualitative aspect (i.e. 
focus groups), used to find reasons for trends in responses (Creswell, 2003). A stratified 
sampling method was applied and only doctors, nurses and pharmacists from the chosen sites 
were invited to participate.  
3.3 POPULATION AND SAMPLE SIZE    
 
In 2016, the hospital employed a total of 623 medical doctors, 2165 nurses and 26 pharmacists. 
This is a total of 2814 permanent health care professionals. The following formula was used to 
calculate an appropriate sample size:  
Sample Size: 
𝑠𝑠 = 	𝑍%	×	 𝑝 	×	(1 − 𝑝)	𝑐%  
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Correction for Finite Population:  𝑛𝑒𝑤	𝑠𝑠 = 	 𝑠𝑠1 +	𝑠𝑠 − 1𝑝𝑜𝑝  
 
Where: 
Z = Z value (e.g. 196 for 95% confidence level) 
p = percentage  picking a choice, expressed as decimal 
(0.5 used for sample size needed) 
c = confidence interval, expressed as decimal 
(e.g., 0.04 = ±4) 
pop = population 
Using a confidence interval of 0.05 and a 95% confidence level, the appropriate sample size for 
this study was 338 health care professionals.  
 
3.4 INCLUSION CRITERIA  	
• All qualified and registered medical doctors, nurses and pharmacists practising in the ten 
chosen wards in 2016/ 2017, including interns and those conducting community service.  
• Participants who consented participation in the study.  
 
3.5 EXCLUSION CRITERIA  	
• Health care professionals other than doctors, nurses and pharmacists were excluded from 
the study.  
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• Basic and post-basic pharmacists were not included in the study.  
• Those who did not consent to participate were not included in the study. 
 
3.6 QUESTIONNAIRE AND FOCUS GROUP DESIGN  	
A literature review was conducted between January and March 2016 to gain background 
knowledge on the perceptions of healthcare workers on ADR reporting globally. A questionnaire 
was then compiled consisting of questions relating to knowledge, attitudes and practices of 
health care professionals. A total of 21 questions were used based on 3 similar studies (Desai et 
al., 2011; Pimpalkhute et al., 2012; Suyagh, Farah & Farha, 2014). In order to achieve the aim of 
the study, the questions were categorised as follows: 5 questions pertaining to demographics; 7 
questions on the awareness of ADR reporting; 7 questions about the professional’s previous 
ADR reporting involvement; 1 question pertaining to the professional’s general attitude towards 
ADR reporting and 1 question about possible future improvements that could be made.  
Following the results from the questionnaire, a focus group guide was designed to address the 
various trends that developed relating to the perceptions held by healthcare workers about ADR 
reporting. These open-ended questions aimed to address the health care professional’s 
perceptions of ADR monitoring, including the patient’s awareness of ADR reporting; the 
professional’s general attitude towards ADR reporting; the professional’s previous ADR 
reporting involvement; and the possible improvements that could be made (see Appendix C).  
3.7 BASELINE ASSESSMENT: QUESTIONNAIRE  	
Participation in the questionnaire phase of the study occurred in the period between July and 
November 2016, in which the hard copies of the questionnaires were disseminated and collected. 
The questionnaires were distributed to pharmacists, and to head nurses at wards, who distributed 
and collected the questionnaires within their departments. Reminders were sent to heads of 
department beforehand to ensure that staff members were made aware of the study. Those who 
choose to participate were required to complete the informed consent form and were given 
appropriate instructions for filling out the questionnaire. They were guaranteed anonymity with 
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regards to their questionnaire responses, in that no personal or identifiable information was asked 
to be disclosed. Only the researchers involved had access to the questionnaires after they were 
completed.  
3.8 FOCUS GROUPS  	
Focus groups are used widely in the field of health science for their unique ability to “seek 
explanations for behaviour” (Lakshman, 2000). Following the questionnaire phase of the study, 
the focus group phase was aimed at understanding the reasons behind certain trends in 
questionnaire responses. The focus group platform was intended to provide further insight, 
possibly even drawing on the opinions expressed in the questionnaires. For purposes of 
continuity from the questionnaires to the focus groups, nurses and pharmacists were exclusively 
chosen to participate, as they represented a combined 86% of the questionnaire participants.  
Nurses and pharmacists in the participating wards were subsequently invited via email and in 
person to attend focus groups (12-20 nurses and 12-20 pharmacists). It was unknown whether 
participants of the focus group had also participated in the questionnaire, due to the anonymity of 
the questionnaire. The groups (nurses and pharmacists) were randomly divided in half (6-10 
participants per group), and 1 group of pharmacists and 1 group of nurses received training 
during their focus group discussion, while the others only received a brief training session at the 
end. Training sessions were conducted during focus groups because the size of the groups, and 
the unique setting provided a favourable platform for training. It utilised the effects of group 
dynamics as a teaching tool, allowing participants to involve themselves and bounce ideas off 
one another, in order to develop understanding of the material.  This also allowed for a variety of 
themes to develop during the sessions.   
The focus groups were based on a broad set of questions (Appendix C), but deviated depending 
on responses from participants. Each focus group took an average of 1 hour. Information 
gathered during the focus groups did not disclose any personal or identifiable information.   
The training material used during focus groups addressed the concepts of PV and ADRs; details 
of the reporting process; and benefits of reporting. The aim of the material is to communicate 
both the process and the importance of reporting ADRs to healthcare professionals.  
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3.9 DATA ANALYSIS  	
Data was collected in the form of questionnaire responses from pharmacists, doctors and nurses. 
The data was then electronically captured on to spreadsheets on Microsoft Excel™. The 
questionnaire responses was categorized in terms of the following:  
Ø The demographics of the person participating.  
Ø The current knowledge and awareness of the participant.   
Ø The attitude of the professional towards PV. 
Ø Any prior PV involvement the participant may have had (i.e. practices).  
Ø The need for further PV training or other suggestions. 
The data captured on Microsoft Excel™ spreadsheets was imported on Stata® (Version 14). 
Pearson chi squared and Fishers tests were run in order to discover significant associations in the 
data, at a significance level of p<0.001. The principles of Braun and Clarke (2006) were applied 
to the qualitative data from the focus groups. The original focus group recordings were 
transcribed once and then confirmed for accuracy. The transcriptions were then coded based on 
emerging concepts and ideas, and finally analysed in terms of the themes and subthemes that 
developed during each focus group discussion.   
 
3.10 VALIDITY OF THE STUDY  	
3.10.1 External Validity and Transferability  
The sample for the study was all participating medical doctors; nurses and pharmacists working 
within the 10 chosen wards and the hospital pharmacy, representing the overall study population 
of the healthcare workers at the study site. Conclusions drawn in this study are specific to the 
hospital site, and therefore generalisations made pertain only to the study population.  
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3.10.2 Construct Validity  
Face and content validity were evaluated in this section. Face validity was achieved in that the 
objectives of the study were appropriately measured using the methodology, which was adapted 
from previous similar studies. The questionnaire was validated using a group of 10 randomly 
selected  pharmacists, who were not included in the study. The questionnaire was piloted once, 
and again one month later in order to ensure validity and eliminate bias. All the questionnaire 
responses were analysed to yield an understanding of relevant and irrelevant questions. The 
questionnaire was adjusted appropriately to obtain a final version for distribution.  
3.10.3 Internal Validity and Credibility  
The primary consideration in this section was the effects of social interaction on the study. The 
study assessed three separate groups of health care professionals (doctors; nurses and 
pharmacists) in the questionnaire, and then two groups (nurses and pharmacists) in the focus 
groups. Knowledge that the study was happening may have affected the participants responses in 
anticipation of what the study involved. Those that chose to respond to the questionnaire or 
participate in the focus groups may have done so with some level of bias.  
3.10.4 Conclusion Validity  
With regards to relationships among quantitative data, chi-squared tests were used to prove the 
statistical significance of any relationship that occurred between variables. With regards to the 
focus group, the quantitative data from the questionnaire was taken into consideration to look for 
continuity or lack thereof. These are explained in the results and discussion chapters.  
	
3.11 RELIABILITY AND DEPENDABILITY OF THE STUDY  	
The study could be easily reproduced in a different study population in order to assess the 
knowledge, attitudes and practices of health care professionals in other settings. However, it is 
not necessarily expected that the results will be consistent in another setting, although similarities 
may occur, based on the literature review of similar studies and their results.  
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3.12 ETHICS  
 
The questionnaire remained anonymous and confidential throughout, with only the researcher 
having access to the forms. The focus groups were recorded and participants were required to 
sign a recording consent form. No personal or identifying information was associated with the 
recording or the transcript. Only the researcher, supervisors and ethics committee, if necessary, 
may listen to the recordings, which will be destroyed after the appropriate time (see Appendix D 
and Appendix E). 
 Ethics approval was granted by the University of the Witwatersrand Human Research Ethics 
Committee (HREC) (No. M160246) (see Appendix F).  
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CHAPTER IV: RESULTS AND DATA ANALYSIS  
 
4.1 QUESTIONNAIRE RESULTS 	
Two hundred and ninety-seven questionnaires were returned out of the sample size calculated of 
338, giving a 87.87% response rate. The respondents were made up of 41 doctors; 230 nurses; 24 
pharmacists and 2 people did not indicate their profession (Table 4.11). The female gender 
represented more than 83% of the sample, which is a statistically significant difference in gender 
(p<0.001) (Table 4.1.2).  
Figure 4.1.1 shows the distribution of health care professionals in the wards, with most 
participants who stated “other” practising in the pharmacy and not in the wards.  
 
4.1.1 Demographics Of Participants   	
Table 4.1.1: Frequency Distribution of the Demographics of Participants (N=297) 
Demographic Characteristics Frequency (N) Percentage (%) 
Gender 
Male  48  16.16 
Female  249   83.84 
Total 297  
Profession 
Doctor  41  13.80 
Nurse 230  77.44 
Pharmacist  24  8.08 
Total  295 (*= 2)  
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Demographic Characteristics Frequency (N) Percentage (%) 
Level of Practice 
Intern  27  9.09 
Community Service 28  9.43 
Post- community service  144  48.48 
Total  199 (*= 98)  
Ward 
Pulmonology 20  6.73 
Oncology  26  8.75 
ICU 38  12.79 
Surgical  56  18.86 
Orthopaedic  39  13.13 
Renal 40  13.47 
Gynaecology  34  11.45 
Diabetes 16  5.39 
Gastroenterology  48  16.16 
Cardiac  37  12.46 
Other  24  7.10 
“Theatre” 1   
“Pharmacy”  9   
“Paediatric oncology”  1   
“Anaesthesiology”  1   
“Haematology”  1   
Total   378  
Years of Practice 
< 1 year 34 11.45 
1-5 years 83 27.95 
6-10 years  106 35.69 
> 10 years  68 22.90 
			 50 
Total  291 (* = 6)  
 
*= missing data  
	
Figure 4.1.1: Distribution of Participants in Wards 	
Table 4.1.2: Gender of Participants Versus Profession of Participants (N=297) 
  Profession of Participants 
Gender Doctor  Nurse  Pharmacist All 
Female  25 (58.14%) 209 (90.87%) 15 (62.50%) 249 (83.84%) 
Male  18 (41.86%) 21 (9.13%) 9 (37.50%) 48 (16.16%) 
Total  43 (100%) 230 (100%) 24 (100%) 297 (100%) 
Pearson Chi-square =  37.4158,	p	value	=	0.000																																																																																																				
The	results	are	significant	at	p<0.001	
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4.1.2 Knowledge of the Participant 
 
Fifty percent of the participants stated they knew how to report an ADR, and 77.10% stated that 
they were familiar with the form. Fifty nine percent of the participants identified the NADEMC 
as the primary place to report ADRs, shown by Figure 4.1.2. Participants chose many reasons for 
the importance of ADRs, with most participants checking all the options for that question shown 
by the distribution in Figure 4.1.3.  
Table 4.1.3: Frequency Distribution of Participants Knowledge of PV (N=297) 
Responses  Frequency (%) Percentage (%) 
Knowing how to report an ADR 
Yes 149 50.17 
No  145 48.82 
Total 294 (*=3)   
Familiar with the reporting form 
Yes 229 77.10 
No  65 21.89 
Total  294 (*=3)   
The National Adverse Event Monitoring 
Centre (NADEMC) 
176 59.26 
Pharmaceutical and Therapeutics Committee 
(PTC) 
145 48.82 
The Medicines Control Council (MCC) 143 48.15 
Medical Supply Depot (MSD) 38 12.79 
The Safety and Quality Subcommittee  70 23.57 
Other  12 4.04 
"Doctor and Pharmacy in Hospital" 3   
"Pharmaceutical Company" 1   
"The Drug Controller" 2   
"Supplier"     
Total  584   
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Table 4.1.4: Frequency Distribution of Participants Knowledge of PV (N=297) 
Continued  
Responses  Frequency (%) Percentage (%) 
Why its important to report ADRs 
To identify new ADRs 1375 92.59 
To improve patient safety 1401 94.34 
To measure the incidence of ADRs 1376 92.66 
To share information about ADRs with 
colleagues 
1347 90.71 
To identify relatively safe drugs 1357 91.38 
It is a requirement 1315 88.55 
 
*= missing data 
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Figure 4.1.2: The Percentage of Where to Report ADRs 
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There was a statistical difference in the knowledge of how to report ADRs by profession 
(p<0.001). Fifty percent of the nurses stated they didn’t know how to report, while 53.59% of 
doctors and 82.61% of pharmacists knew how to report (Table 4.1.4). This is depicted visually in 
Figure 4.1.4 with the responses (“yes” or “no”) shown by profession.  
 
Table 4.1.5: Knowledge of How to Report ADRs by Profession (N=292) 
 Profession of Participant 
Response Doctor Nurse Pharmacist All 
Yes 23  
(53.49%) 
(15.65%) 
105  
(46.46%) 
(71.43%) 
19  
(82.61%) 
(12.93%) 
147  
(50.34%) 
(100%) 
No 18  
(41.86%) 
(12.59%) 
121  
(53.54 %) 
(84.62%) 
4  
(17.39%) 
(2.80%) 
143  
(48.97%) 
(100%) 
Invalid Response 2  
(4.65 %) 
(100%) 
0  
(0.00%) 
(0%) 
0  
(0.00%) 
(0%) 
2  
(0.68%) 
(100%) 
Total  43  
(100%) 
(14.73%) 
226  
(100%) 
(77.40%) 
23  
(100%) 
(7.88%) 
292  
(100%) 
(100%) 
 Pearson Chi-square =  23.1900,   p-value = 0.000, Fisher's exact for scores <5 = 0.000             
The results are significant at p<0.001  
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Figure 4.1.4: Knowledge of Reporting by Profession 
 
Table 4.1.5 and Table 4.1.6 below show the participants knowledge of how to report by the years 
of experience and level of practice respectively. Fifty-four percent of participants who knew how 
to report had been practising as health care professionals for 6-10 years. Statistically, participants 
who were newest to practising (<1 year) had little knowledge of reporting with 76.47% of 
participants stating they didn’t know how to report (p<0.001). Fifty-eight percent of post-
community service participants knew how to report ADRs, whereas only 23.08% of interns knew 
how to report ADRs (p<0.001).  
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Table 4.1.6: Knowledge of How to Report ADRs by Years of Experience of Participants (N=288) 
 Years of Experience of Participants 
Response  <1 year 1-5 years 6-10 years >10 years  All 
Yes 6  
(17.65%) 
(4.08%) 
34  
(41.46%) 
(23.13%) 
57  
(53.77%) 
(38.78%) 
50  
(75.76%) 
(34.01%) 
146 (51.04%) 
(100%) 
No  26  
(76.47%) 
(18.71%) 
48  
(58.54%) 
(34.53%) 
49  
(46.23%) 
(35.35%) 
16  
(24.24%) 
(11.51%) 
139 
(48.26%) 
(100%) 
Invalid Response 2  
(5.88%) 
(100%) 
0 
(0.00%) 
(0.00%) 
0  
(0.00%) 
(0.00%) 
0  
(0.00%) 
(0.00%) 
2  
(0.69%) 
(100%) 
Total  34  
(100%) 
(11.81%) 
82  
(100%) 
(28.47%) 
106  
(100%) 
(36.81%) 
66  
(100%) 
(22.92%) 
288  
(100%) 
(100%) 
Pearson Chi-square- =  47.2773,   p-value = 0.000,  Fisher's exact for scores <5 = 0.000                        
The results are significant at p<0.001 
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Table 4.1.7: Knowledge of How to Report ADRs by Level of Practice of Participant (N= 195) 
 Level of Practice of Participants 
Response  Intern Community 
Service 
Post- Community 
Service 
All 
Yes 6  
(23.08%) 
(6.00%) 
12  
(42.86%) 
(12.00%) 
82  
(58.16%) 
(82.00%) 
100  
(51.28%) 
(100%) 
No  18  
(69.23%) 
(19.35%) 
16  
(57.14%) 
(17.20%) 
59  
(41.84%) 
(63.44%) 
93  
(47.69%) 
(100%) 
Invalid Response 2  
(7.69%) 
(100%) 
0  
(0.00%) 
(0.00%) 
0  
(0.00%) 
(0.00%) 
2  
(1.03%) 
(0.00%) 
Total  26  
(100%) 
(13.33%) 
28  
(100%) 
(14.36%) 
141  
(100%) 
(72.31%) 
195  
(100%) 
(100%) 
Pearson	Chi-square=		22.7846,	p-value	=	0.000,	Fisher's	exact	for	scores	<5	=	0.001																		
The	results	are	significant	at	p<0.001		
With regards to the knowledge of the reporting form, participants were asked if they had seen the 
form previously after seeing an example of one in the questionnaire. The table below (Table 
4.1.7) shows that 77.89% of participants had seen the form before. Eighty-one percent of 
doctors, 75.00% of nurses and all (100%) of the pharmacists had seen the form before. The chi-
squared test conducted shows that there was an insignificant difference between professions in 
this regard  (p>0.001).  
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Table 4.1.8: Knowledge of Reporting Form by Profession (N= 294) 
 Profession of Participants 
Response Doctor Nurse Pharmacist All 
Yes 35  
(81.40%) 
(15.28%) 
171  
(75.00%) 
(74.67%) 
23  
(100%) 
(10.04%) 
229  
(77.89%) 
(100%) 
No 8  
(18.60%) 
(12.31%) 
57  
(25.00%) 
(87.69%) 
0  
(0.00%) 
(0.00%) 
65  
(22.11%) 
(100%) 
Total 43  
(100%) 
(14.63%) 
228  
(100%) 
(77.55%) 
23  
(100%) 
(7.82%) 
294  
(100%) 
(100%) 
Pearson	Chi-square=		7.9417,	p-value	=	0.019,	Fisher's	exact	for	scores	<5=	0.007																							
The	null	hypothesis	is	true	at	a	significance	level	of	p<0.001	
	
Table 4.1.8 shows the knowledge of the reporting form by the level of practice of participants. In 
line with knowledge of how to report, 86.01% of post-community service professionals were 
familiar with the reporting form. However, although there was a low percentage of interns who 
knew how to report an ADR, more than 60% (61.54%) of interns had seen the form before.  
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Table 4.1.9: Knowledge of Reporting Form by Level of Practice of Participants (N=197) 
 Level of Practice 
Response Intern Community Service Post-Community 
Service 
All 
Yes 16  
(61.54%) 
(10.39%) 
15  
(53.57%) 
(9.74%) 
123  
(86.01%) 
(79.87%) 
154  
(78.17%) 
(100%) 
No 10  
(38.46%) 
(23.36%) 
13  
(46.43%) 
(30.23%) 
20  
(13.99%) 
(46.51%) 
43  
(21.83%) 
(100%) 
Total 26  
(100%) 
(13.20%) 
28  
(100%) 
(14.21%) 
143  
(100%) 
(72.59%) 
197  
(100%) 
(100%) 
Pearson Chi-square=  19.3007, p-value= 0.000, Fisher's exact for scores <5 = 0.000               
The results are significant at p<0.001 
 
Similarly, Table 4.1.9 shows the participants knowledge of the reporting form by the years of 
experience. Participants who had been practising longer were more familiar with the form, with 
91.8% of people practising for >10 years having previously seen the form. Only 21.03% of 
participants were unfamiliar with the reporting form, with 44.12% of participants practising <1 
year. There is an association between the years of experience and familiarity with the reporting 
form (p<0.001). 
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Table 4.1.10: Knowledge of Reporting Form by Years of Practice of Participants (N=290)  
 Years of Experience of Participants 
Response <1 year 1-5 years 6-10 years >10 years All 
Yes 19  
(55.88%) 
(8.30%) 
59  
(71.08%) 
(25.76%) 
89  
(84.76%) 
(38.86%) 
62  
(91.18%) 
(27.07%) 
229  
(78.97%) 
(100%) 
No  15  
(44.12%) 
(24.59%) 
24  
(28.92%) 
(39.34%) 
16  
(15.24%) 
(26.23%) 
6  
(8.82%) 
(9.84%) 
61  
(21.03%) 
(100%) 
Total 34  
(100%) 
(11.72%) 
83  
(100%) 
(28.26%) 
105  
(100%) 
(36.21%) 
68  
(100%) 
(23.45%) 
290  
(100%) 
(100%) 
Pearson	Chi-square=	22.2389,	p-value=	0.000,	Fisher's	exact	for	scores	<	5	=	0.000																				
The	results	are	significant	at	p<0.001	
	
4.1.3 Attitudes of the Participants towards PV 
 
Table 4.1.10 shows the frequency distribution of the results pertaining to the attitudes of the 
participants towards PV. Ninety percent of participants stated they would report an ADR based 
on the seriousness of the reaction, shown by Figure 4.1.5 with the other cases most likely to be 
reported by participants. Factors such as not knowing how to report; not knowing where to 
report; managing the patient being more important than reporting; and reporting being time-
consuming, made up most of the factors that discouraged participants from reporting. Figure 
4.1.6 shows participant’s opinions on which health profession should be held responsible for 
reporting ADRs. Ninety-three percent of participants felt medical practitioners should be held 
responsible, followed by 88.89% for nurses and 76.77% for pharmacists. Two percent of 
participants chose “other” which was made up of the response “patients”. This was further 
broken down in Figure 4.1.7, which shows the profession of participant and corresponding 
			 61 
response of who should report. Nurses, pharmacists and doctors themselves believed doctors 
should be held responsible for reporting before other health care professionals. 
Table 4.1.11: Frequency Distribution of Participant's Attitudes (N=297) 
Response Frequency (N) Percentage (%) 
Cases most likely to report ADR 
Seriousness of the ADR 268 90.24 
Unusualness of the reaction 160 53.87 
Involvement of a new drug  139 46.80 
Level of certainty that it is an ADR 85 28.62 
None of the above  2 0.67 
Total  654  
Factors discouraging participants from reporting ADRs 
Do not know how to report 97 32.66 
Not knowing where to report 96 32.32 
Did not think it was important to report  65 21.89 
Managing the patient was more important 
than reporting ADRs 
115 38.72 
Lack of access to ADR reporting form 49 16.50 
Patient confidentiality  46 15.49 
It is time-consuming  95 31.99 
There is a lack of feedback after forms have 
been submitted  
65 21.89 
Other 7 2.36 
"Inexperience" 1  
"No discouraging factors" 2  
Total  635  
ADRs that should be reported 
None 1 0.34 
All ADRs  182 61.28 
All serious ADRs 132 44.44 
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Response Frequency (N) Percentage (%) 
ADRs that should be reported (continued) 
ADRs to new drugs 59 19.87 
Unknown ADRs to old drugs 47 15.82 
ADRs to herbal and non-allopathic drugs  23 7.74 
ADRs to vaccinations 28 9.43 
Other 3 1.01 
Total  475  
Professionals who should report ADRs 
Medical practitioners 275 92.59 
Nurses 264 88.89 
Pharmacists 228 76.77 
Other 7 2.36 
"Patient" 2  
Total  774  
Reference materials participants would use 
Textbook 177 59.60 
Colleague 211 71.04 
Internet 236 79.46 
Package Insert 224 75.42 
Other 3 1.01 
Total  851  
*= missing data  
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Figure 4.1.5: Percentage of Cases Most Likely to be Reported by Participants 
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Figure 4.1.6: Perceived Responsibility for Reporting ADRs 	
 
Figure 4.1.7: Percentage of who should report according to each profession 
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4.1.4 Previous PV Practices of Participants  	
Table 4.1.11 shows previous PV activity in which participants may have been involved, of which 
only 10.77% of participants had received previous PV training, and the majority of participants 
(73.74%) submitted <1 ADR per year. There was a significant difference between the percentage 
of participants who encountered an ADR in practice  (58.59%), and those who reported the 
encountered ADR (16.50%) (p<0.001). This information is shown in table 4.1.12 and figure 
4.1.8. There was also an association between the participants who attended workshops/seminars 
and those who had knowledge of reporting (Table 4.1.13). Of the participants who had 
previously attended a seminar, 96.88% answered “yes” when asked whether they knew how to 
report ADRs (p<0.001). This brings up the importance of training when dealing with healthcare 
worker’s knowledge. When looking at the percentage of those having attended a workshop 
versus those that reported ADRs (Table 4.1.14), 48.15% reported <1 ADR per year; and 11.11% 
reported <1 ADR per month.   
Table 4.1.12: Frequency Distribution of Previous PV Activity (N=294) 
Response Frequency (N) Percentage (%) 
Any previous training seminars/workshops on ADR reporting? 
Yes  32 10.77 
No  262 88.22 
Total  294 (* =3)  
Are ADR reporting forms easily available to you in practice? 
Yes  176 59.26 
No  93 31.31 
Total  269 (* =28)  
Have you ever encountered an ADR in practice? 
Yes  174 58.59 
No  115 38.72 
Total  289 (* =8)  
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Have you ever reported an ADR that you encountered? 
Yes  49 16.50 
No  238 80.13 
Total  287 (* =10)  
How many ADR reports have you submitted on average? 
<1/ year 219 73.74 
1-10/ year 23 7.74 
<1/month 5 1.68 
1-10/ month 2 0.67 
Total  249 (* =48)  
*= missing data  
 
Table 4.1.13: Participants who Encountered ADRs Versus those that Reported the Encountered 
ADR (N=285) 
 Reported an Encountered ADR  
Encountered an ADR Yes No  Total  
Yes 47                     
(27.17%)               
(95.92%) 
126                          
(72.83%)               
(53.39%) 
173                      
(100%)            
(60.70%) 
No  2                           
(1.79%)               
(4.08%) 
110                      
(98.21%)              
(46.61%) 
112                         
(100%)            
(39.30%) 
Total  49                         
(17.19%)             
(100%) 
236                       
(82.81%)             
(100%) 
285                                          
(100%)                  
(100%) 
Pearson	Chi-square=	30.7645,	p-value=	0.000																																																																																																	
The	results	are	significant	at	p<0.001	
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Figure 4.1.8: Participants who encountered an ADR versus those who reported the encountered ADR 	
Table 4.1.14: Knowledge of How to Report ADRs by Previous Training (N=292) 
 Knowing how to report an ADR  
Have you previously attended an ADR 
Training Seminar/Workshop? 
Yes No  Invalid 
Response  
Total  
Yes 31      
(96.88%) 
(21.09%) 
1        
(3.13%)      
(0.70%) 
0                     
(0.00%)        
(0.00%) 
32              
(100%) 
(10.96%) 
No 116 
(44.62%) 
(78.91%) 
142 
(54.62%)   
(99.30%) 
2                           
(0.77%)           
(100%) 
260               
(100%) 
(89.04%) 
Total  147 
(50.34%)  
(100%) 
143 
(48.97%) 
(100%) 
2                           
(0.68 %)          
(100%) 
292              
(100%  
(100%) 
Pearson Chi-square= 31.1291, p-value= 0.000, Fisher's exact = 0.000                                                     
The results are significant at p<0.001 
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Table 4.1.15: Number of ADR Reports Submitted by Previous Training (N= 248)  
 Number of ADR Reports Submitted 
Have you previously attended an ADR 
Training Seminar/Workshop? 
<1/year 1-10/ year <1/month 1-10/ 
month 
Total  
Yes 13         
(48.15%)         
(5.96%) 
0             
(0.00%)       
(0.00%) 
3      
(11.11%)           
(60.00%) 
0        
(0.00%)         
(0.00%) 
27            
(100.00%)       
(10.89%) 
No 205         
(92.76%)               
(94.04%) 
12         
(5.43%)            
(52.17%)  
2             
(0.90%)         
(40.00%) 
2               
(0.90%)           
(100.00%) 
221       
(100.00%)            
(89.11%) 
Total  218         
(87.90%)        
(100.00%) 
23         
(9.27%)                 
(100.00%) 
5             
(2.02%)          
(100.00%) 
2               
(0.81%)           
(100.00%) 
248       
(100.00%)        
(100.00%) 
Pearson Chi-square= 50.4708,  p-value = 0.000, Fisher's exact = 0.000                                                 
The results are significant at p<0.001 
 
4.1.5 The Need for Further PV Training or other Suggestions 
 
Table 4.1.15 shows the participant’s suggestions for improving PV, with workshops and 
seminars making up most of the responses (59.93%). Figure 4.1.9 shows this with a ranking of 
what participants chose as suggestions for improvement. Education for nurses and paramedicals 
(54.88%) and bulletins on ADRs (52.86%) followed closely. Figure 4.1.10 further categorises 
the information by years of experience, with generally equal distribution.  
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Table 4.1.16: Frequency Distribution of Suggestions Offered to Improve PV 
Suggestions for Improvement  Frequency (N)  Percentage (%) 
ADR reporting made mandatory 113 38.05 
Workshops and seminars 178 59.93 
Pharmacovigilance teaching programmes for 
undergraduates, interns and postgraduates.  
136 45.79 
Education for nurses and paramedicals 163 54.88 
Monthly meetings of rare ADRs 118 39.73 
Bring out bulletins on ADRs 157 52.86 
Other 13 4.38 
"Streamlined process, access to forms, 
access to fax" 
1  
"Shorter form"  1  
Total  878  
 
 
	
Figure 4.1.9: Suggestions for Improvement 
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Figure 4.1.10: Suggestions for Improving ADR Reporting by Years of Practice 
	
4.2 FOCUS GROUP RESULTS  
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possibly permanent. Side effects were not seen as necessary to report, particularly because they 
are often known or expected to happen, as one participant explained:  
“Normally what I would tell a patient is (that) certain rashes appear as side effects. But 
if it becomes severe, you just monitor that and then, well you have to stop them and 
report it…You know certain rashes comes and goes…I don’t see that as an ADR” 
(Pharmacist, Group 1, Female).  
Nurses in the second group identified a few examples of ADRs, such as: 
“For example: antibiotics, they have a lot of adverse effects. Like Stephen Johnson's 
syndrome- we saw a patient with that recently. Grey (baby) syndrome as well”          
(Nurse, Group 2, Female) 
Both nurses and pharmacists demonstrated an awareness of ADRs in practice, being able to 
name examples and recount recent incidences within the wards. However, this knowledge didn’t 
necessarily extend to the reporting of ADRs. Pharmacists admitted to learning about how to 
report ADRs recently by a pharmacist of authority, however some pharmacist participants were 
unaware of where the form went after handing it to the drug controller at the pharmacy. On the 
other hand, nurses in one group were mostly unaware of the form, and confusion occurred 
between participants about where to find forms in the wards. In the second focus group of nurses, 
participants were unaware of the existence of the form altogether, stating they had never seen it 
before. Many participants felt it should be placed in patient files as that would make the process 
more convenient. Pharmacists showed some understanding for the role of the PTC at the 
hospital, having seen meetings held once a month, while nurses were not aware of the role of the 
PTC at the hospital.  
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Table 4.2.1: Knowledge of the Participant 
                       Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
Knowledge 
of PV and 
ADRs 
Adherence  The detection and 
reporting of adverse drug 
reactions  
Serious side-
effects  
Not aware of the term 
‘pharmacovigilance’ 
Different to a side effect 
because its unknown  
Different to a side effect 
in that an ADR is life 
threatening  
Defined by 
severity  
Aware of ADRs 
giving examples of 
skin reactions; Steven 
Johnson’s and Grey 
Baby Syndrome with 
antibiotics 
Different to a side effect 
because its more serious/ 
life threatening  
  Difference between 
side effect and 
adverse effect 
identified as side 
effects being 
unpleasant but non-
life-threatening  
 A reaction that comes 
and goes is not believed 
to be an ADR 
 
   
Knowledge 
of what to 
report  
Report serious adverse 
reactions, not side 
effects  
Reactions that are 
expected/ common 
shouldn’t be reported 
  
Don’t report known 
reactions   
   
Awareness of 
the form  
Not Aware Awareness of the form 
only during internship or 
undergraduate studies, 
but not since 
Not Aware  Not Aware 
Recently been made 
aware by someone of 
authority (i.e. drug 
controller) 
Recently been made 
aware by someone of 
authority (i.e. drug 
controller) 
Aware of it but 
its unavailable in 
the ward 
 
   Aware of it but 
unaware of where 
to find it  
 
   Reporting form 
attached to 
admission form, 
but is not put into 
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patient files 
Knowledge 
of how/where 
to report  
Send patient to doctor 
(refer) when an adverse 
drug reaction is 
encountered  
Forms ultimately sent to 
the NADEMC 
Not Aware  No knowledge of 
where the form goes 
 No knowledge of where 
the form goes 
Forms referred with 
patient to doctor  
Not Aware of the 
existence of a 
PTC 
No knowledge of how 
to report 
 Aware of the existence 
of a PTC  
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4.2.2 Attitudes PV Practices of Participants 
 
In each focus group, participants believed that ADR reporting was of significant importance in 
health care. In the first group of pharmacists, one participant explained ADRs to be:  
“of high importance because it creates a database of what to expect”             
(Pharmacist, Group 1, Female).  
This opinion was echoed by a nurse who understood that a record of adverse effects should be 
kept after the drug is put on the market.   
Factors found to encourage reporting included feedback being provided; certainty that what is 
observed clinically is an ADR; diminished patient compliance; witnessing reactions that progress 
rapidly; and those that are not listed in the package insert. One group of pharmacists discussed a 
new-found understanding that pharmacists have the ability and expertise to be able to report 
ADRs, and thus felt encouraged to do so. Similarly, a nurse participant felt reporting protected 
her as a nurse, in that it was her professional obligation to report anything that could be harmful 
to a patient.  
During discussions on factors that discourage participants from reporting, a range of reasons 
were given (summarized in the tables below). These included reporting being time consuming, 
and a lack of patient contact time (for pharmacists); reporting not being within the scope of 
practice for pharmacists/ nurses; polypharmacy leading to an uncertainty of what the causative 
agent could be; lack of knowledge; fear of being held liable; the form being too long to complete 
during working hours; and the lack of communication among members of the health care team. 
Lack of communication and lack of feedback was a common theme that developed among the 
groups, as one nurse explained: 
“I think the thing that is inhibiting people (from) recording (ADRs) is lack of 
communication by the multidisciplinary team members. If you report to the pharmacy, 
they keep the data, they don’t come back to me to give you an intervention – do this or 
stop this drug, use this one. So maybe it's like what's the use of doing this”               
(Nurse, Group 2, Female).  
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Lack of feedback after a form was submitted made the reporting health care professional less 
likely to report in the future, assuming reporting didn’t lead to anything. A pharmacist recounted 
a product quality report she had previously submitted, and explained how receiving feedback 
from the pharmaceutical company had encouraged her to continue reporting in the future.  
In terms of liability, one group of nurses feared liability and as a result refrained from claiming 
responsibility by signing the form. On the other hand, the second group of nurses felt as if taking 
responsibility for the witnessed ADR by recording what was observed further protected them and 
the patient involved as well. Participants who had been practising for a shorter amount of time 
seemed to be more likely to claim responsibility and report the ADR personally.    
Also based on the years of practice, one nurse explained a lacking culture of reporting in the 
wards, leading to continuing lack of reporting with newer nurses: 
“It's a vicious cycle because, because they don't do it, the next generation nobody is 
going to do it”                                                                                                                 
(Nurse, Group 2, Female).  
 
Table 4.2.2: Attitudes of the Participants towards PV 
 Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
Importance 
of reporting 
ADRs  
Of high importance 
because it creates a 
database of what to 
expect  
 Important 
because it 
prevents further 
complications 
Important because it 
prevents the patient from 
getting the medication 
again 
    Important because there 
may be an issue with the 
specific batch, which 
should be recalled 
    Important because after 
clinical trials, there needs 
to be a way of recording 
possible adverse effects 
Reasons to 
report   
Certainty that it is an 
ADR 
Receiving feedback 
is an encouraging 
factor to continue 
reporting  
Any reaction that 
isn’t listed in the 
package insert  
Reactions that increase in 
frequency or severity 
should be reported  
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 If feedback is 
provided, reporting 
will be more likely in 
the future 
All cases should be 
reported for the 
realization that they 
could become 
progressively more 
serious 
A reaction that 
spreads or gets 
rapidly worse 
should be 
reported  
Feelings that reporting 
what you see protects you 
as a nurse 
 In situations where 
patient compliance is 
diminished due to the 
reaction 
Feelings that 
pharmacists have the 
information and 
ability to report. 
Pharmacists also see 
patients monthly for 
repeats and are more 
likely to know of 
reactions experienced 
by outpatients 
  
Reasons for 
not 
reporting/ 
under-
reporting  
Time-consuming 
process  
Mild or expected 
reactions don’t need 
to be reported  
A known/ 
expected 
reaction does not 
need to be 
reported  
Not necessary to report a 
suspected/ known reaction 
 Patient contact time is 
not enough for proper 
counseling with 
regards to ADRs 
Feelings that patients 
only claim to have a 
reaction to be put on 
a preferred drug  
Lack of 
knowledge  
Participants identified a 
possible problem of nurses 
not feeling like it’s their 
responsibility to report 
 
 
 
 Any reaction that is 
already listed in the 
package insert (i.e. 
known or expected) 
does not need to be 
reported  
Insufficient time with 
the patient and being 
short staffed  
Mild reactions 
don’t need to be 
reported, the 
reaction will 
resolve once the 
doctor changes 
the drug  
Lack of communication 
between the multi-
disciplinary team 
members, and a lack of 
feedback as a result 
 Feelings that patients 
claim to have a 
reaction in order to get 
a preferred drug over 
the prescribed drug 
Polypharmacy leads 
to an uncertainty 
about which drug 
caused the reaction 
Nurses are not 
responsible for 
reporting as they 
were not the 
ones prescribing 
the medicine  
Senior staff members lack 
of reporting leads to an 
unawareness of reporting  
 Mild reactions don’t 
need to be reported 
because they will 
resolve themselves 
Not being aware of 
reactions due to 
insufficient patient 
counselling  
The reporting 
form does not 
contain a “space” 
for a nurse to 
report  
Participants felt that nurses 
will only do what is 
compulsory  
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4.2.3 Previous PV Practices of Participants 
 
With regards to the participant’s previous PV practices, pharmacists were able to recall a few 
cases of ADRs witnessed, but very few reported. These results were consistent with the 
questionnaire results. Most pharmacist participants were under the impression that it is more 
within the scope of practice of a doctor to report ADRs, and as a result most pharmacists had 
previously referred the patient back to the doctor with the reporting form in the event of a 
suspected reaction, as one pharmacist explained:   
“Stop it immediately, go see the doctor. Report to the doctor, there is a specific form that 
you need to fill in with the doctor and then bring it back. Some of them go back” 
(Pharmacist, Group 1, Female).  
Participants in the same group also mentioned a specific case that was not reported due to a lack 
of knowledge about the correct channel of reporting. They further cited a lack of time and patient 
contact to be able to report the ADR, adding to the reason for referral. Although the pharmacists 
continued to refer suspected ADRs, they consistently mentioned a lack of feedback, and 
communication within the health disciplines:  
 
 
Reasons for 
not 
reporting/ 
under-
reporting 
(continued) 
 
 
Pharmacist Group 1 
 
 
Pharmacist Group 2 
 
 
Nurse Group 1 
 
 
Nurse Group 2 
Feeling as if the doctor 
has the authority 
 A lack of time  The length of the form is 
discouraging 
Having to report on 
paper versus a 
computer based 
system 
 Reluctance to 
report for fear 
that it would be 
claiming 
responsibility for 
the incident 
(liability) 
Positive attitude towards 
reporting in the future, 
given the instructions on 
how and where to report; 
and understanding the 
importance of reporting 
Feeling as if no 
resolution is reached 
after a report is 
submitted 
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“So you would actually say “take the form, go to the doctor, speak to the doctor about it. 
Maybe the doctor can substitute it with something else”. But there is no follow up, you 
see,… did it help or did it not help. We are not aware of what happens next”    
(Pharmacist, Group 1, Female).  
One pharmacist recounted an incident of reporting in which she became more aware that 
reporting is within the scope of practice of a pharmacist:  
“I sent it with the patient to the doctor…I told him to take it to the doctor and the doctor 
sent it back saying that even the pharmacist can do it…I had to ask him what happened, 
and I took the patient’s details” (Pharmacist, Group 2, Female). 
The nurses similarly believed ADR reporting to be within the scope of practice of doctors, and 
admitted to regular patient referrals. As a result, none of the nurses within the group could recall 
the process of reporting, and had never submitted an ADR report.  
With regards to general PV practices, both pharmacists and nurses had told patients to stop the 
drug and refer to the doctor to substitute the drug with another, when in the presence of a 
reaction of any kind. Inquiries about drug interactions were rare in both groups. The pharmacists 
generally seemed to check the interactions within the medicines dispensed, but didn’t always ask 
patients about concurrent medicines taken, although acknowledging the growing trends of 
polypharmacy and self-medication. Herbal and traditional medicines were rarely considered 
when counselling a patient.  
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Table 4.2.3: Previous PV Practices of Participants 
                 Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
Specific 
cases 
Previous reporting 
didn’t include reporting 
by pharmacist, cases 
usually referred to a 
doctor who may 
choose to report. 
Insufficient patient 
contact time cited as 
the reason for referral 
Case of a rash with 
leflunomide  was reported by 
the pharmacist  
No previous 
“ADRs” claimed 
to be witnessed 
Steven Johnson’s 
Syndrome witnessed 
in the ward. Patient 
was discharged with 
oral antibiotics and 
was readmitted 
following the start 
of Steven Johnson’s. 
Participants were 
unaware if any 
reporting occurred 
 A patient presenting 
with a rash from taking 
a cephalosporin was 
not reported due to not 
knowing the correct 
port of call 
Previous product complaints 
have been reported, and 
followed up by the company 
involved 
Steven Johnson’s 
Syndrome 
witnessed but not 
thought of as 
being a possible 
ADR 
 
  Swelling of the feet with 
amlodopine  was seen and 
referred to the doctor, but not 
reported 
  
  Allergies to excipients    
General PV 
Practices 
Instruct patient to stop 
drug, contact doctor to 
change the drug, but no 
reporting activity 
occurs 
 The package 
insert of a 
medicine is 
checked when a 
reaction occurs 
When there is a 
known side effect 
with a specific drug, 
preventative 
measures are taken 
by participants to 
avoid the effect/ add 
to patient comfort  
 No reporting activity 
because no training had 
previously been given 
on how to report; the 
last time ADRs were 
explained was during 
undergraduate training 
 
 
 
  Any reaction 
noticed is verbally 
reported to the 
doctor 
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 Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
Promotion 
of patient 
awareness  
Inform patients of 
possible expected 
reactions, or to be 
aware of anything out 
of the ordinary, and to 
report this to the doctor 
Patients should be 
encouraged to be vocal about 
any symptoms or possible 
reactions that occur 
  
 Fear of the placebo 
effect when warning a 
patient of possible 
reactions  
   
Inquiries/ 
warnings 
about drug 
interactions 
 Drug interactions with 
alcohol are generally 
mentioned  
Warnings about drug-drug 
interactions are limited to 
alcohol 
Inquiries into 
concomitant drugs 
not always made   
 
 Interactions with ARVs 
always checked 
   
 Food-drug interactions 
rarely discussed 
   
 
 
Interactions with 
complementary 
medicines rarely 
discussed  
   
 
4.2.4 The Need for Further PV Training or Other Suggestions  
	
A few subthemes developed during the discussions on training and future suggestions. Most 
participants spoke about a lack of training and thus a lack of knowledge on how to report 
ADRs. Participants responded by saying they would be more likely to report given proper 
training/ instructions. One nurse recalled never having learned about ADR reporting and 
suggested adding it to the undergraduate pharmacology curriculum for nurses. A pharmacist 
mentioned the need for routine training seminars: 
“We were aware of it…you study, you learn about it but you just stop learning. And I 
think the same for the nurses. So if they can just make it accessible and someone 
inform them, like what was done with us…”                                                       
(Pharmacist, Group 1, Female) 
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With regards to the ADR reporting form, all participants had concerns about the length of the 
form, as well as the accessibility of the form. Nursing participants were not entirely aware of 
where the form was kept, and suggested the forms form part of each patient file:  
“Maybe it should form part of our file… when we give the medication. After or under 
the prescription chart, it should also be there so if you come across anything of that 
sort you don't start looking for the form”                                                                  
(Nurse, Group 1, Female).  
Use of mobile applications as an alternative to the paper based form were discussed with each 
group, with mixed opinions. Most participants felt as if it was a more convenient and efficient 
method, while one pharmacist felt it was a less reliable method.  
One idea that was discussed in each group was having a designated person(s) in charge of PV, 
perhaps a pharmacist to whom all health care professionals can refer patients with suspected 
ADRs.  
A nurse in the second group felt it would be important to get pharmacists more patient contact 
time through ward rounds, explaining that it would provide a way for pharmacists to use their 
pharmacology expertise and work with nurses to monitor patients:  
“I also think that if there was a drive to put pharmacist on ward rounds, that that 
would really help”                                                                                                       
(Nurse, Group 2, Female).  
Education in the form of posters was mentioned both in terms of reminding health care 
professionals to report and how to report, as well as promoting patient awareness. Many 
pharmacists felt it was important to empower patients, so that out-patients will be more alert 
while on their medication, and more communicative with the pharmacist about potential 
problems. This was mentioned in response to issues of a lack of patient contact due to time 
constraints, and polypharmacy:  
 “Patients here go to multiple doctors and they independently prescribe”        
(Pharmacist, Group 1, Female).  
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Therefore, patient awareness developed as a theme as pharmacists believed it would give 
them a more complete picture of the patient’s health and medication.  
Nurses felt having posters and visual aids in the wards would serve as a reminder to report, as 
well as a convenient guide on how and where to do so. In the same way, both pharmacists and 
nurses were eager to become more aware of adverse effects, with one pharmacist asking:  
“Is there an available database for the public? Or for us as a professionals to actually 
have access to in terms of pharmacovigilance”                                                        
(Nurse, Group 1, Pharmacist).  
The concept of a PV bulletin, in which all health care professionals are kept updated on PV 
issues and trends, was discussed in this regard. This was also seen as a way to amalgamate the 
different health disciplines by keeping all health professionals aware and involved in the 
issues of PV.    
Finally, the idea of incentivizing PV was explored with nurses and pharmacists believing it 
should form part of professional development points.  
Table 4.2.4: The Need for Further PV Training or Other Suggestions 
 Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
Training  No previous training 
given 
 Training 
seminars should 
be conducted 
regularly, 
particularly 
because shifts 
change 
In-service training 
said to be the best 
way to approach 
nurses 
 Future training 
encouraged by 
someone within the 
pharmacy 
  Educating/ 
training during 
undergraduate 
pharmacology 
courses. 
Comparisons were 
made to learning 
about antibiotic 
stewardship and 
consequently 
being weary of 
this in the wards 
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Suggestions  Use of a mobile 
application  
Making reporting 
mandatory  
The form should 
be made more 
available in daily 
practice  
Having 
pharmacists on 
ward rounds for 
referral on drug 
interactions etc.  
 Pharmacist Group 1 Pharmacist Group 2 Nurse Group 1 Nurse Group 2 
 Forms be made more 
accessible  
Having a 
pharmacovigilance 
pharmacist (a person in 
charge of PV at the 
pharmacy) to whom other 
pharmacists can refer 
patients  
Being made 
aware of ADR 
trends in the 
province (i.e. 
bulletin) 
Incentivising 
reporting using 
professional 
development 
points 
 Encourage patient 
awareness through 
use of posters 
Making use of a 
counselling room when 
an ADR is suspected to 
ensure privacy and time 
to assess the patient and 
fill out the form 
The form should 
be made to 
include 
“reporting nurse” 
Incentivising 
reporting using 
awards like 
certificates within 
the wards 
 Appoint a person to 
be in charge of PV in 
the pharmacy 
Encourage patient 
awareness through use of 
posters 
 Posters detailing 
how to report 
should be placed 
in the wards to 
remind nurses of 
the process 
Educational 
posters with 
information about 
ADRs and 
reminders on 
checking patients 
for ADRs 
 Being made aware of 
trends in ADRs via a 
bulletin  
Involving all pharmacists 
and post-basic pharmacy 
assistants by discussing 
ADR trends within the 
hospital at meetings 
Boxes should be 
placed in each 
ward containing 
blank reporting 
forms, and a 
place to put 
completed forms 
Having a more 
concise form  
 The use of black box 
warnings  
 It should be made 
mandatory to 
report any seen 
ADRs 
Having one 
designated person 
for 
pharmacovigilance 
who will deal with 
the paperwork and 
referrals  
   Use of a mobile 
application would 
make it more 
convenient to 
report  
Using stickers/ 
notes on patients 
charts when an 
ADR is suspected, 
and then referring 
to the pharmacy 
who will report 
accordingly 
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    Using mobile 
applications to 
report quicker  
    Having a 
computerized 
system which has 
all the patients 
information and 
medication 
history, which can 
also be used to 
report suspected 
ADRs 
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CHAPTER V: DISCUSSION  	
5.1 DEMOGRAPHICS 	
The questionnaire phase of the study had a response rate of 87.87%, comparable to that of 
previous similar studies (Pimpalkhute et al., 2012; Gupta & Udapa, 2011; Elkami et al., 2011; 
Mulatu & Worku, 2014). The respondents consisted of 41 medical doctors (13.80%); 230 nurses 
(77.44%); and 24 pharmacists (8.08%). This distribution was largely due to the number of health 
care professionals working at the hospital, which in 2016 consisted of 623 medical doctors, 2165 
nurses and 26 pharmacists (shown in the sample size calculation in Chapter III: Methodology). 
The demographic of the participants was also largely female (83.84%), with 90.97% of nursing 
participants, and 62.50% of pharmacist participants being female. According to the South 
African Nursing Council (SANC) website, the number of registered nurses was totalled at 
approximately 55 337 (Gauteng Province) in 2016, made up of 92.68% females and 7.32% males 
(South African Nursing Council, 2017). Similarly, according to the South African Pharmacy 
Council (SAPC), there are approximately 16 340 pharmacists made up of 62.39% females and 
37.61% males (South African Pharmacy Council, 2017). These statistics may serve to explain the 
imbalance of gender in the study.   
 
5.2 KNOWLEDGE OF HEALTH CARE PROFESSIONS ON ADR REPORTING 
 
Health care professionals have demonstrated a relative awareness for the presence of ADRs in 
studies similar to this one, including that of Fadare et al. (2011), and Pimpalkhute et al. (2012). 
However, these studies also found a lack of awareness of the process of reporting. Fadare found 
that although 93.8% of participants had knowledge of reasons to report ADRs, only 39.5% of 
participants were aware of the actual reporting form (Fadare et al., 2011). Similarly, Alsaleh et 
al. found that 72.6% of participants were able to correctly define ADRs, while only 7% were 
aware of the reporting system of the country (2017). According to Suyagh, Farah and Farha, only 
28.6% of hospital pharmacists were aware of the reporting system in Jordan (2014).  
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In this current study, the questionnaire results showed that 50.17% of participants knew how to 
report ADRs, and 77.10% were aware of the yellow reporting form. Yet, during focus group 
sessions, participants did not demonstrate knowledge of the process of ADR reporting.  
In terms of knowledge of the pharmacovigilance reporting system, 59.26% of participants 
identified the NADEMC as the place to report ADRs, while only 48.82% chose the PTC as an 
option. Nurses were unaware that PTCs existed, but most pharmacists knew about the role of the 
PTC at the hospital, which was confirmed during focus group discussions. Fadare et al. found a 
similar figure with 44.6% of participants who were aware of the existing hospital committee 
(2011). Although the NADEMC is a national monitoring centre, the PTC should also be 
recognised as an important channel for communication within the institution. Provincial PTCs 
play a significant role in the collection of ADR reports. Ideally, the gathering of reports for 
provincial PTCs is a function that happens through the Safety and Quality Subcommittee, which 
physically gathers and collates the data, looking for potential concerning trends. Communication 
and integration among all health care professionals may help to give holistic care, and in many 
ways can make the involved persons more motivated to report in the future.  
The study found different levels of knowledge among the different professions. Nurses had the 
least awareness of how to report (46.46%) , followed by doctors (53.49%) and then pharmacists 
(82.61%) (p< 0.001). During focus group discussions, nurses drew on the theme of responsibility 
and accountability. Many nurses didn’t believe reporting ADRs was a professional nursing 
obligation, and believed that referring patients who presented with a reaction was the correct step 
to take. De Angelis et al. concluded that “Nurses are not fully aware of their role in adverse drug 
reaction reporting” (2015, pp.1), and Hanafi et al. had a similar finding with 89% of nurses 
preferring to refer the report to the doctor for completion (Hanafi et al., 2014). With regards to 
perceived responsibility, nursing respondents in the questionnaire identified themselves and 
doctors to be mostly responsible for reporting ADRs, while placing little responsibility on 
pharmacists. This result was inconsistent with the focus groups, in which nurses felt least 
equipped to report.     
Health care professional’s knowledge of the flow of reporting as well as their awareness of who 
should take responsibility of reporting need to be enforced. This brings up the need to train heath 
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care professionals more constantly, through the use of in-service training and more formalised 
classroom-based learning at the undergraduate level. This idea was also posed by Pimpalkhute 
who noticed gaps in “undergraduate training” (2012, p. 60). Olsson, Pal and Dodoo noted the 
importance of introducing PV training into undergraduate studies (2015). An approach targeted 
at students saw a “student- run pharmacovigilance programme” being piloted in the Netherlands 
(Netherlands Pharmacovigilance Centre, 2017). This common theme of education at the 
undergraduate level is largely important to the field , as Rajiah,  Maharajan and Nair echoed in 
their study (2015). These findings were also consistent with that of Elkami et al. who found that 
deficiencies in the undergraduate curriculum lead to a lack of knowledge about 
pharmacovigilance (Elkami et al., 2011). 
This current study also found a statistical association between knowledge of ADR reporting and 
the years of experience of participants. Participants who are newer to practising as health care 
professionals seemed to have knowledge of the importance of reporting, however there is a lack 
of knowledge of the process itself (p<0.001). Only 23.08% of interns knew how to report ADRs, 
while 61.45% had seen the reporting form before (p< 0.001).  
 
5.3 ATTITUDES OF HEALTH CARE PROFESSIONALS ON ADR REPORTING 	
Attitudes in this study were measured by the factors that encouraged and discouraged health care 
workers, as well as the cases in which they were most likely to report ADRs. These factors 
accounted for some of the gaps between knowledge and practice. Understanding the importance 
of ADR reporting is an inevitable start to reporting ADRs, and this study found that only 21.89% 
of participants chose “did not think it was important to report” as a reason for underreporting. 
Similarly, Gupta and Udapa found that 89.5% of doctors thought reporting was an important part 
of their profession (2011), and Joubert and Naidoo found that 79.4% of participants “regarded 
PV as a valuable tool” (Joubert & Naidoo, 2016, p.243). Focus group sessions were consistent 
with questionnaire findings in this regard, as most participants thought reporting was important, 
and were even able to list reasons as to why this is so.   
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A range of factors discouraged participants from reporting, with “managing the patient was more 
important than reporting”, “do not know how to report”, and “do not know where to report” 
being the most frequently answered. “Ignorance about the reporting system” found in this study 
was consistent with the results of Desai et al. Most health care professionals cited the seriousness 
of the ADR (90.24%) as the main encouraging factor in deciding whether to report an ADR, 
comparable to the 88.9% found by Gupta and Udapa (2011).  
In 1996, an attitudinal survey study by Inman listed 7 of the most frequently cited reasons for 
underreporting of ADRs. The focus groups conducted in this study brought up many common 
themes, with the fear of litigation; the need for incentives; and time-related excuses being 
particularly mentioned in each group. With regards to fear, De Angeles et al. mentioned fear as a 
possible “extrinsic issue” related to the institution itself (2014). Focus group sessions shed light 
on this issue as participants who were newer to practising seemed to be less fearful, feeling as if 
reporting a patient’s reaction will in fact protect them as health care professionals. Fear of being 
held liable is perhaps a factor that could be dealt with during in-service training of nurses, as 
there is a need for nurses to understand what reporting ADRs can achieve. Vallano et al. found 
similar problems in focus group sessions with doctors and also discovered that many doctors 
aren’t aware of the benefits of the system of pharmacovigilance (2005).  	
5.4 PRACTICES OF HEALTH CARE PROFESSIONALS ON ADR REPORTING 
  
The practices of health care professionals were assessed through responses based on encountered 
ADRs versus reported ADRs. Fifty-nine percent of participants had encountered an ADR in 
practice, yet only 16.50% reported the encountered ADR (p<0.001). Fadare et al. discovered that 
although 59.26% of participants said they knew how to report an ADR in the questionnaire, 
73.74% of participants submitted <1 ADR/ year (2011).   
Vallano et al. found the availability of reporting forms to be a major barrier of reporting (2005). 
In this study, although 59.26% of participants stated the forms were easily available to them in 
practice, participants in focus group sessions weren’t aware of where to find the form. This issue 
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is one that should be addressed at each institution and brings up the need for heads of department 
to play a role in integrating pharmacovigilance into the topics discussed at routine meetings.  
 
5.5 SUGGESTIONS AND FUTURE RECOMMENDATIONS 
  
Education should remain a priority in the field of pharmacovogilance, and the idea of training 
was a fundamental point of discussion during focus group sessions. Workshops and seminars 
was the most frequently suggested improvement to make during the questionnaire phase, and this 
was echoed by mentions of this during focus group sessions. Nurses felt ADR reporting would 
become part of their daily practice given proper training and empowerment, and pharmacists 
acknowledged that a lack of proper training led to ignorance about reporting. 96.88% of 
participants who had previously attended a training seminar stated they knew how to report 
ADRs. Similarly, De Angelis et al (2015); Lopez-Gonzalez (2009); Backstrom et al. (2002); 
Sevene et al. (2008); and Cereza et al. (2010) found increases in reports after training, and higher 
rates of reports from health care professionals with a higher level of education. Sevene et al. 
(2008); and Kaselekela Oscar & Boyd (2017) focused on pharmacovigilance in resource-limited 
countries, and mentioned continuous training, public awareness and the importance of feedback 
in reporting ADRs.   
Training should be consistent starting from the undergraduate level and continuing into routine 
training sessions in the workplace (Granas et al., 2007); (Li et al., 2014); (Rehan et al., 2002); 
(Rajiah, Maharajan & Nair, 2015).	Furthermore, health care professionals want to be kept up to 
date and involved, and so PV bulletins and meetings may be of great use once the culture of 
reporting is established. The use of posters and other visual aids may be of some use as a quick 
reference during daily practice in the wards, and in the pharmacy. Nurses in particular felt this 
would be helpful to them, and pharmacists felt they should even be used in patient waiting areas 
to remind out-patients to be alert and aware of potential adverse effects. Thoughts of increasing 
awareness through campaigns was also mentioned by Gupta and Udapa (2011).    
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CHAPTER VI: PROBLEMS AND LIMITATIONS  	
The study was conducted in 10 wards, and the pharmacy at one institution. The data obtained and 
conclusions drawn were specific to this environment, however similar studies could be done in 
other hospitals in order to get a more complete picture of PV in South Africa.  
CHAPTER VII: FUTURE RECOMMENDATIONS AND APPLICATIONS  	
This study was conducted at one institution, in which the following recommendations can be 
made: 
• Training for health care professionals from the undergraduate level to in-service training 
in the working environment (wards; pharmacy dispensary). 
• Visual aids such as posters put up around the hospital to remind health care professionals 
of the process of reporting; and patient-awareness posters. 
• Designating one pharmacist and one nurse in each ward to be in charge of PV. 
Similar studies which evaluate the pharmacovigilance system at other institutions could be 
performed in order to properly assess the baseline knowledge, attitudes and practices of health 
care professionals in other environments. From this, further recommendations could be made.   
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CHAPTER VIII: CONCLUSION  
 
Low to middle income countries often lack the resources and financial backing to allow the 
systems of PV to function the way they do in wealthier countries. However, the nature of 
spontaneous reporting is such that it is inexpensive and relies on health care professionals, or in 
some case patients, working within the framework of manually reporting the witnessed ADR to 
the relevant authority. This study assessed the knowledge, attitudes and practices of health care 
professionals, in order to obtain an idea of the reasons for the underreporting of ADRs, as well as 
ways this can be improved. It was found from this study that knowledge of the process of 
reporting needs to be enhanced. Some participants articulated that although they once had a basic 
understanding of pharmacovigilance and the activity of adverse drug reaction reporting, a lack of 
practice and training while on the job created a culture of non-responsibility. Attitude is thus 
perhaps the most important factor when it comes to reporting ADRs as unless it is a mandatory 
professional obligation, many health care workers see little benefit in reporting. However, if the 
culture of reporting is instilled at the undergraduate level, and then reinforced in the workplace, 
the attitudes of health care professionals may improve. The safety, quality and efficacy of 
medicines are pivotal factors to the health science industry, and they are ones that shouldn’t be 
ignored. Health care professionals should be made to understand the importance that lies in the 
post-marketing monitoring of drugs, primarily in terms of the safety and wellbeing of patients 
who take drugs to improve their health.  								  
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APPENDICES 
Appendix A: ADR and Product Quality Problem Report Form 
	
 
ADVERSE DRUG REACTION AND PRODUCT QUALITY PROBLEM REPORT FORM 
(Identities of reporter and patient will remain strictly confidential ) 
NATIONAL ADVERSE DRUG EVENT MONITORING CENTRE 
           Medicines Control Council,        Tel : (021) 447-1618 
          The Registrar of Medicines ,        Fax: ( 021) 448-6181 
           Department of Health  
Department 
of Health 
Logo Here 
In collaboration with the WHO International Drug Monitoring Programme 
    
PATIENT INFORMATION 
 
Name (or initials): ......................................................... Age:.............................   Weight (kg) :.............................. 
Sex:: M F  DOB :...... / ........./ ........  Height (cm) :.............................. 
 
ADVERSE REACTION/PRODUCT QUALITY PROBLEM 
 
Adverse reaction1  and/or Product Quality problem2  Date of onset of reaction: :......./......../...... 
Time of onset of reaction: .......h.........min 
     
Description of reaction or problem (Include relevant tests/lab data, including dates): 
 
 
 
 
 
 
 
1. MEDICINES/VACCINES/DEVICES (include all concomitant medicines) 
Trade Name & Batch No. 
(Asterisk Suspected Product) 
Daily Dosage Route Date Started Date Stopped Reasons for use 
      
      
      
      
      
      
ADVERSE REACTION OUTCOME (Check all that apply) 
    
 death  life-threatening Event reappeared on rechallenge: Recovered:     Y  N 
 disability  hospitalisation  Y  N  Rechallenge not done  Sequelae:  Y  N 
 congenital anomaly  Other................ Treatment (of 
reaction)..................................................... 
Describe Sequelae:....................... 
 required intervention to ............................... ............................................................................................
... 
....................................................... 
 prevent permanent 
impairment/damage 
............................... 
............................... 
............................................................................................
............................................................................................
..... 
..............................................................
................................................ 
 
COMMENTS: (e.g. Relevant history, Allergies, Previous exposure, Baseline  test results/lab data) 
 
 
 
 
2. PRODUCT QUALITY PROBLEM: 
Trade Name Batch No Registration No Dosage form & strength Expiry Date Size/Type of container 
      
      
 
Product available for evaluation?: Y   N
 
REPORTING DOCTOR/PHARMACIST Etc:   
 
NAME: .....................................................................................   QUALIFICATIONS:................................................................. 
 
ADDRESS: ...............................................................................   ................................................................       ................................ 
                                                                                                                   Signature                 
Date ....................................................................................................             
 
TEL: (.........)............................    
 
This report does not constitute an admission that medical personnel or the product caused or contributed to the event. 
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(Medicine Control Council, n.d.) 
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Appendix B: Questionnaire  	
		Please	take	a	few	minutes	of	your	time	to	fill	out	this	questionnaire	about	your	thoughts	and	opinions	on	Adverse	Drug	Reaction	(ADR)	reporting	at	Charlotte	Maxeke	Academic	Hospital.	Please	note	this	questionnaire	is	anonymous.		Please	tick	or	cross	the	appropriate	boxes.			
1.	What	is	your	gender?				
Male	 	 	 Female	 	
	
2.	What	is	your	profession?		 	
Doctor	 	 	 Nurse	 	 	 Pharmacist	 	
(Please	specify	level	of	practice)	
	
3.	Please	specify	your	type	of	practice.		
Intern		 	 	 Community	Service	 	 	 Post-	Community	Service		 	
			 105 
	
4.	In	which	ward	do	you	practice?		
Pulmonology	 	 	 Oncology	 	 	 ICU	 	
Surgical	 	 Orthopaedic	 	 Renal		 	
Gynaecology	 	 Diabetes	 	 Gastroenterology	 	
Cardiac	 	 	
	
5.	For	how	many	years	have	you	been	practising?			
<1	year	 	 	 1-5	years	 	
6-	10	years	
	
	 >10	years		 	
	
6.	Have	you	ever	attended	a	training	seminar/workshop	on	ADR	reporting?		
Yes	 	 	 No	 	
	
7.	Do	you	know	how	to	report	an	ADR?		
Yes	 	 	 No	 	
	
8.	Have	you	ever	seen	the	form	shown	below?			
Yes	 	 	 No	 	
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9.	Are	ADR	reporting	forms	easily	available	to	you	in	practice?			
 
ADVERSE DRUG REACTION AND PRODUCT QUALITY PROBLEM REPORT FORM 
(Identities of reporter and patient will remain strictly confidential ) 
NATIONAL ADVERSE DRUG EVENT MONITORING CENTRE 
           Medicines Control Council,        Tel : (021) 447-1618 
          The Registrar of Medicines ,        Fax: ( 021) 448-6181 
           Department of Health  
Department 
of Health 
Logo Here 
In collaboration with the WHO International Drug Monitoring Programme 
    
PATIENT INFORMATION 
 
Name (or initials): ......................................................... Age:.............................   Weight (kg) :.............................. 
Sex:: M F  DOB :...... / ........./ ........  Height (cm) :.............................. 
 
ADVERSE REACTION/PRODUCT QUALITY PROBLEM 
 
Adverse reaction1  and/or Product Quality problem2  Date of onset of reaction: :......./......../...... 
Time of onset of reaction: .......h.........min 
     
Description of reaction or problem (Include relevant tests/lab data, including dates): 
 
 
 
 
 
 
 
1. MEDICINES/VACCINES/DEVICES (include all concomitant medicines) 
Trade Name & Batch No. 
(Asterisk Suspected Product) 
Daily Dosage Route Date Started Date Stopped Reasons for use 
      
      
      
      
      
      
ADVERSE REACTION OUTCOME (Check all that apply) 
    
 death  life-threatening Event reappeared on rechallenge: Recovered:     Y  N 
 disability  hospitalisation  Y  N  Rechallenge not done  Sequelae:  Y  N 
 congenital anomaly  Other................ Treatment (of 
reaction)..................................................... 
Describe Sequelae:....................... 
 required intervention to ............................... ............................................................................................
... 
....................................................... 
 prevent permanent 
impairment/damage 
............................... 
............................... 
............................................................................................
............................................................................................
..... 
..............................................................
................................................ 
 
COMMENTS: (e.g. Relevant history, Allergies, Previous exposure, Baseline  test results/lab data) 
 
 
 
 
2. PRODUCT QUALITY PROBLEM: 
Trade Name Batch No Registration No Dosage form & strength Expiry Date Size/Type of container 
      
      
 
Product available for evaluation?: Y   N
 
REPORTING DOCTOR/PHARMACIST Etc:   
 
NAME: .....................................................................................   QUALIFICATIONS:................................................................. 
 
ADDRESS: ...............................................................................   ................................................................       ................................ 
                                                                                                                   Signature                 
Date ....................................................................................................             
 
TEL: (.........)............................    
 
This report does not constitute an admission that medical personnel or the product caused or contributed to the event. 
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Yes	 	 	 No	 	
	
10.	To	whom	should	you	report	ADRs?	You	may	tick/cross	more	than	one	box.		
The	National	Adverse	Event	Monitoring	Centre	(NADEMC)	 	 	 Pharmaceutical	and	Therapeutics	Committee	(PTC)	 	
The	Medicines	Control	Council	(MCC)	 	 Medical	Supply	Depot	(MSD)	 	
The	Safety	and	Quality	Subcommittee		 	 Other		 	
	
If	you	selected	“other”,	please	specify:		
	
	
11.	Have	you	ever	encountered	an	ADR	in	practice?	
Yes	 	 	 No	
	
12.	Have	you	ever	reported	an	ADR	that	you	encountered?	
Yes	 	 	 No	
	
13.	How	many	ADR	reports	have	you	submitted	on	average?		
<1/	year	 	 	 1-10/	year	 		
<1/month	
	
	 1-10/	month	 	
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14.	Why	is	it	important	to	report	ADRs?	Please	rate	on	a	scale	from	1	to	5,	1	being	not	
important	and	5	being	very	important.		
Reason	 1	 2	 3	 4	 5	
To	identify	new	ADRs	
	
	 	 	 	 	
To	improve	patient	safety	
	
	 	 	 	 	
To	measure	the	incidence	of	ADRs	
	
	 	 	 	 	
To	share	information	about	ADRs	with	colleagues	 	 	 	 	 	
To	identify	relatively	safe	drugs	
	
	 	 	 	 	
It	is	a	requirement	
	
	 	 	 	 	
	
15.	In	which	of	the	following	cases,	are	you	most	likely	to	report	an	ADR?	You	may	
tick/cross	more	than	one	box.	
Seriousness	of	the	ADR	 	 	 Unusualness	of	the	reaction	 	
Involvement	of	a	new	drug		 	 Level	of	certainty	that	it	is	an	ADR	 	
None	of	the	above		 	 	
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16.	What	are	the	factors	that	discourage	you	from	reporting	ADRs?	You	may	tick/cross	
more	than	one	box.	
Do	not	know	how	to	report	 	 	 Not	knowing	where	to	report	 	
Did	not	think	it	was	important	to	report		 	 Managing	the	patient	was	more	important	than	reporting	ADRs	 	
Lack	of	access	to	ADR	reporting	form	 	 Patient	confidentiality		 	
It	is	time-consuming		 	 There	is	a	lack	of	feedback	after	forms	have	been	submitted		 	
Other	 	
	
If	you	selected	“other”,	please	specify:		
	
	
17.	In	your	view,	which	ADRs	should	be	reported?	You	may	tick/cross	more	than	one	box.	
None	 	 	 All	ADRs		 	
All	serious	ADRs	 	 ADRs	to	new	drugs	 	
Unknown	ADRs	to	old	drugs	 	 ADRs	to	herbal	and	non-allopathic	drugs		 	
ADRs	to	vaccinations	 	 Other	 	
	
If	you	selected	“other”,	please	specify:		
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18.	In	your	opinion,	which	of	these	professionals	should	report	ADRs?	You	may	tick/cross	
more	than	one	box.	
Medical	practitioners	 	 	 Nurses	 	
Pharmacists	 	 Other	 	
	
If	you	selected	“other”,	please	specify:		
	
19.		If	you	think	a	patient	is	experiencing	an	ADR,	how	would	you	check	the	information?	
You	may	tick/cross	more	than	one	box.	
Textbook	 	 	 Colleague	 	
Internet	 	 Package	Insert	 	
Other	 	 	 	
	
20.	Do	you	agree	or	disagree	with	the	following	statements?	Please	rate	on	a	scale	from	1	
to	5,	1	being	strongly	disagree	and	5	being	strongly	agree.	
Statement		 1	 2	 3	 4	 5	
ADR	reporting	is	a	professional	obligation	 	 	 	 	 	
I	know	how	to	report	an	ADR	 	 	 	 	 	
I	have	received	sufficient	ADR	reporting	training	 	 	 	 	 	
I	know	how	to	fill	out	a	NADEMC	form	 	 	 	 	 	
ADR	reporting	adds	up	to	unnecessary	workload	 	 	 	 	 	
An	allergic	reaction	to	a	medicine	is	an	ADR	 	 	 	 	 	
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I	always	check	the	patient’s	allergies	before	I	give	them	any	medicine	 	 	 	 	 	
I	would	like	to	receive	more	training	on	ADR	reporting	 	 	 	 	 	
I	have	seen	a	patient	experience	an	ADR	 	 	 	 	 	
Nobody	really	benefits	if	I	report	an	ADR	 	 	 	 	 	
	
21.	Do	you	have	any	suggestions	about	how	reporting	can	be	improved?	You	may	
tick/cross	more	than	one	box.	
ADR	reporting	made	mandatory	 	
Workshops	and	seminars	 	
Pharmacovigilance	teaching	programmes	for	undergraduates,	interns	and	postgraduates.		 	
Education	for	nurses	and	paramedicals	 	
Monthly	meetings	of	rare	ADRs	 	
Bring	out	bulletins	on	ADRs	 	
Other	 	
	If	you	selected	“other”,	please	specify:		
	
	
We	thank	you	for	your	co-operation!		
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Appendix C: Focus Group Question Guide  
 
1. What is your understanding of the term ‘pharmacovigilance’? 
2. What do you understand by the term ‘adverse drug reaction’? 
• Expand on what you believe to be the differences between side effects and adverse 
effects, if any.  
3. What are your thoughts on the reporting of Adverse Drug Reactions?  
• Why is it important/ not important.  
4. Can you describe your previous experiences of reporting Adverse Drug Reactions, if any?  
• Witnessing them/ reporting them.  
5. What do you understand about how and where to report ADR’s? 
6. Under what circumstances would you report an ADR? 
• Is it based on how serious the reaction is? 
• Should mild ADR’s be reported?  
7. What are some of the factors that have discouraged you from reporting ADR’s in the past?   
• How can these be changed?  
• What would make reporting ADR’s easier for you?  
• In your opinion, would using a mobile application to report ADR’s be helpful?  
8. Is receiving feedback after submitting forms important?  
9. Do you believe ADR reporting should be made mandatory? 
10. How do you believe hospital staff can be made more aware of the existence of the ‘Adverse Drug 
Reaction and Product Quality Problem Report Form’? 							
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Appendix D: Participant Information Document for Questionnaire  	
Study	Title:		
Evaluating	and	Improving	Frameworks	for	Adverse	Drug	Reaction	Reporting	
	
Dear	Participant		
We	 are	 conducting	 a	 study	 to	 determine	 the	 current	 perceptions	 of	 doctors,	 nurses	 and	 pharmacists	
with	regards	to	the	pharmacovigilance	activity	of	adverse	drug	reaction	reporting	at	Charlotte	Maxeke.	
The	purpose	of	the	study	is	to	gain	an	understanding	of	the	knowledge,	attitude	and	practices	of	health	
care	professionals	with	regards	to	Adverse	Drug	Reaction	(ADR)	reporting.		
Participants	 (doctors,	 nurses	 and	 pharmacists)	 will	 be	 asked	 to	 complete	 a	 questionnaire	 about	 ADR	
reporting,	consisting	of	close-ended	questions.		
We	would	 like	you	 to	consider	participating	 in	 this	 study.	The	pages	 to	 follow	contain	all	 the	 relevant	
information	relating	to	the	study.	Should	you	require	any	further	information,	please	feel	free	to	contact	
the	study	researcher	or	supervisors.	
	
Neelaveni	Padayachee		 Neelaveni.Padayachee@wits.ac.za	 011	717	2269	
Belinda	Strydom		 Belinda.Strydom@righttocare.org	 072	369	5430	
Yashmay	Gordhon	 yashmayg@yahoo.com	 079	135	6785	
	
If	you	require	any	additional	information	regarding	your	rights	as	a	research	participant,	or	if	you	have	
any	complaints	regarding	this	research	study,	you	may	contact	the	Chairperson	of	the	Human	Research	
Ethics	Committee,	University	of	the	Witwatersrand:	
	
Prof.	Cleaton	Jones	 011	717	2100	
	
Thank	you	for	taking	time	to	consider	participation.		
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INTRODUCTION		
	
You	are	 invited	to	consider	participating	 in	a	research	study.	Your	participation	 in	this	study	 is	entirely	
voluntary.		
	
1. Before	agreeing	 to	participate,	 it	 is	 important	 to	 read	and	understand	 the	 following	 regarding	
the	 purpose	 of	 the	 study,	 the	 procedures,	 and	 your	 right	 to	withdraw	 from	 the	 study	 at	 any	
time.		
This	 information	 leaflet	will	 help	 you	 decide	 if	 you	would	 like	 to	 participate.	 You	 should	 fully	
understand	what	is	involved	before	you	agree	to	take	part	in	this	study.		
2. You	should	not	agree	to	take	part	unless	you	are	satisfied	about	all	the	procedures	involved.		
3. If	 you	decide	 to	 take	part	 in	 this	 study,	 you	will	 be	 asked	 to	 sign	 an	 informed	 consent	 letter,	
which	confirms	that	you	understand	the	study	and	are	participating	voluntarily.		
	
Some	of	the	most	frequently	asked	questions	you	may	have	are	answered	below:		
WHAT	IS	THE	PURPOSE	OF	THE	STUDY?	
The	purpose	of	the	study	is	to	gain	an	understanding	of	the	knowledge,	attitude	and	practices	of	nurses,	
doctors	and	pharmacists	at	Charlotte	Maxeke	with	regards	to	their	involvement	of	ADR	reporting.			
WHO	IS	INVOLVED	IN	THE	STUDY?		
The	questionnaire	will	 be	open	 to	 all	 doctors,	 nurses	 and	pharmacists	 at	Charlotte	Maxeke	Academic	
Hospital	who	 are	 interested	 in	 participating.	Only	 the	 researchers	 involved	will	 see	 the	 questionnaire	
responses.		
WHAT	DO	I	HAVE	TO	DO?	
You	are	 requested	 to	answer	 the	questions	 contained	 in	 two	questionnaires,	 and	 to	attend	a	 training	
session	on	the	importance	of	ADR	reporting.		
DO	I	HAVE	TO	TAKE	PART?		
• Your	participation	in	this	study	is	entirely	voluntary	and	you	can	decline	to	participate,	or	stop	at	
any	time,	without	stating	any	reason.		
• Non-participation	or	withdrawal	will	not	result	in	any	sanction.		
	
ARE	THERE	ANY	BENEFITS	IF	I	TAKE	PART?		
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ARE	THERE	ANY	DISADVANTAGES	TO	TAKING	PART?		
None	we	are	aware	of.		
WHO	HAS	REVIEWED	AND	GIVEN	ETHICAL	APPROVAL	FOR	THE	STUDY?		
• This	 study	 protocol	 has	 been	 submitted	 to	 the	 University	 of	 the	 Witwatersrand,	 Human	
Research	Ethics	Committee	(HREC)	
	
HOW	 WILL	 MY	 PARTICIPATION	 IN	 THE	 STUDY	 AND	 QUESTIONAIRE	 RESPONSES	 BE	 KEPT	
CONFIDENTIAL?		
• No	 information	 regarding	 your	 participation	 or	 responses	will	 be	 used	 for	 any	 purpose	 other	
than	to	gain	an	understanding	of	the	perception	of	ADR	reporting.			
• At	no	point	in	the	study	will	you	be	asked	to	divulge	any	personal	or	identifiable	information.	
	
WHO	WILL	HAVE	ACCESS	TO	THE	RESULTS	OF	THE	STUDY?		
• The	researchers	and	supervisors	
• The	results	obtained	may	be	presented	to	peers		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Participant		
Name:		
	
Signature:		
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Appendix E: Consent Form and Participant Information Sheet for Focus Groups 
	
	
Consent	Form	and	Participant	Information	Sheet	for	Focus	Groups	
	
Study	Title:	Evaluating	and	Improving	Frameworks	for	ADR	Reporting	
Study	Number:	M160246	
	
INFORMED	CONSENT		
	
Dear	Participant,		
We	are	conducting	a	study	to	determine	the	current	perceptions	of	doctors,	nurses	and	pharmacists	
with	regards	to	the	pharmacovigilance	activity	of	adverse	drug	reaction	(ADR)	reporting	at	Charlotte	
Maxeke	Academic	Hospital.	The	purpose	of	the	study	is	to	gain	an	understanding	of	the	knowledge,	
attitude	and	practices	of	health	care	professionals	with	regards	to	ADR	reporting,	and	to	use	this	
information	to	implement	an	effective	system	of	reporting.		
Each	focus	group	will	contain	approximately	8-10	participants	(2	groups	of	nurses	and	2	groups	of	
pharmacists).	2	groups		(1	group	of	nurses	and	1	group	of	pharmacists)	will	be	chosen	at	random	to	be	
involved	in	a	brief	training	seminar.	The	focus	groups	will	be	based	on	a	broad	set	of	questions	dealing	
with	ADR	reporting.	The	focus	group	will	take	approximately	1	hour	and	will	be	recorded	for	purposes	of	
the	study.	Information	gathered	during	the	focus	groups	will	not	disclose	any	personal	or	identifiable	
information.	
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We	would	like	you	to	consider	participating	in	this	study.	The	pages	to	follow	contain	all	the	relevant	
information	relating	to	the	study.	Should	you	require	any	further	information,	please	feel	free	to	contact	
the	study	researcher	or	supervisors.	
Neelaveni	Padayachee		 Neelaveni.Padayachee@wits.ac.za	 011	717	2269	
Belinda	Strydom		 Belinda.Strydom@righttocare.org	 072	369	5430	
Yashmay	Gordhon	 yashmayg@yahoo.com	 079	135	6785	
	
If	you	require	any	additional	information	regarding	your	rights	as	a	research	participant,	or	if	you	have	
any	complaints	regarding	this	research	study,	you	may	contact	the	Chairperson	of	the	Human	Research	
Ethics	Committee,	University	of	the	Witwatersrand:	
Prof.	Cleaton	Jones	 011	717	2100	
	
Consent	for	Focus	Group:	Name:																												Signature:																													Date:			
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RECORDING	CONSENT	FORM		
	
Study	Title:	Evaluating	and	Improving	Frameworks	for	ADR	Reporting	
Study	Number:	M160246	
Researcher:	Yashmay	Gordhon	
																						Wits	University,	Department	of	Pharmacy	and	Pharmacology		
	
This	study	involves	the	audio	recording	of	the	focus	group.	Neither	your	name	nor	any	other	personal	or	
identifiable	information	will	be	associated	with	the	recording	or	the	transcript.	Only	the	researcher,	
supervisors	and	ethics	committee,	if	necessary,	may	listen	to	the	recordings.		
The	recordings	taken	will	be	transcribed	by	the	researcher	and	erased	after	the	retention	time	frame.	
HSPCA	Standards	recommends	that	recordings	be	destroyed	after	2	years	if	the	research	is	published	or	
6	years	if	unpublished.	Transcripts	of	responses	during	focus	groups	may	be	reproduced	in	whole	or	in	
part	for	use	in	presentations	or	written	products	that	result	from	this	study.	No	identifying	information	
will	be	used	in	said	presentations	or	written	products.		
	
By	signing	this	form,	I	am	allowing	the	researcher	to	record	the	interview	as	part	of	this	research.		
	
	
	
	
	
	
	
	
	
	
Thank	you	for	taking	time	to	consider	participation.		
Participant		
Name:		
	
Signature:		
Researcher	
Yashmay	Gordhon	
	
Signature:		
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PARTICIPANT	INFORMATION	SHEET	
	
INTRODUCTION		
	
You	are	invited	to	consider	participating	in	a	research	study.	Your	participation	in	this	study	is	entirely	
voluntary.		
	
4. Before	agreeing	to	participate,	it	is	important	to	read	and	understand	the	following	regarding	
the	purpose	of	the	study,	the	procedures,	and	your	right	to	withdraw	from	the	study	at	any	
time.		
This	information	leaflet	will	help	you	decide	if	you	would	like	to	participate.	You	should	fully	
understand	what	is	involved	before	you	agree	to	take	part	in	this	study.		
5. You	should	not	agree	to	take	part	unless	you	are	satisfied	about	all	the	procedures	involved.		
6. If	you	decide	to	take	part	in	this	study,	you	will	be	asked	to	sign	an	informed	consent	letter,	
which	confirms	that	you	understand	the	study	and	are	participating	voluntarily.		
	
Some	of	the	most	frequently	asked	questions	you	may	have	are	answered	below:		
	
WHAT	IS	THE	PURPOSE	OF	THE	STUDY?	
The	purpose	of	the	study	is	to	gain	an	understanding	of	the	knowledge,	attitude	and	practices	of	nurses,	
doctors	and	pharmacists	at	Charlotte	Maxeke	with	regards	to	their	involvement	of	ADR	reporting,	and	to	
implement	an	effective	system	of	reporting.		
	
WHO	IS	INVOLVED	IN	THE	STUDY?		
The	study	involves	a	questionnaire	and	4	focus	groups.	The	questionnaire	will	be	open	to	all	doctors,	
nurses	and	pharmacists	at	Charlotte	Maxeke	Academic	Hospital	who	are	interested	in	participating.	The	
questionnaire	responses	will	be	seen	only	by	the	researchers	involved.		
The	focus	group	will	involve	a	small	group	of	nurses	and	pharmacists	at	Charlotte	Maxeke	Academic	
Hospital	who	are	interested	in	participating.	The	focus	group	recordings	will	be	heard	only	by	the	
researchers	involved.		
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WHAT	DO	I	HAVE	TO	DO?	
You	are	requested	to	attend	a	focus	group,	in	which	the	reporting	of	ADRs	will	be	discussed.		
	
DO	I	HAVE	TO	TAKE	PART?		
• Your	participation	in	this	study	is	entirely	voluntary	and	you	can	decline	to	participate,	or	stop	at	
any	time,	without	stating	any	reason.		
• Non-participation	or	withdrawal	will	not	result	in	any	sanction.		
	
ARE	THERE	ANY	BENEFITS	IF	I	TAKE	PART?		
No.		
	
ARE	THERE	ANY	DISADVANTAGES	TO	TAKING	PART?		
None	we	are	aware	of.		
	
WHO	HAS	REVIEWED	AND	GIVEN	ETHICAL	APPROVAL	FOR	THE	STUDY?		
• This	study	protocol	has	been	submitted	to	the	University	of	the	Witwatersrand,	Human	
Research	Ethics	Committee	(HREC)	
	
HOW	WILL	MY	PARTICIPATION	IN	THE	STUDY	AND	QUESTIONAIRE	RESPONSES	BE	KEPT	
CONFIDENTIAL?		
• No	information	regarding	your	participation	or	responses	will	be	used	for	any	purpose	other	
than	to	gain	an	understanding	of	the	perception	of	ADR	reporting.			
• Any	personal	or	identifiable	information	included	in	the	audio	recording	or	transcripts	will	not	
be	used	in	presentations	or	in	written	products	resulting	from	the	study	and	will	only	be	known	
to	the	researcher.		
	
WHO	WILL	HAVE	ACCESS	TO	THE	RESULTS	OF	THE	STUDY?		
• The	researchers	and	supervisors	
• The	results	obtained	may	be	presented	to	peers		
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Appendix F: Ethical Clearance Certificate  
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Appendix G: Approval of Change of Title  		
	
Private Bag 3 Wits, 2050
Fax: 027117172119
Tel:  02711 7172076
Reference:   Mrs Sandra Benn
E-mail: sandra.benn@wits.ac.za
15 August 2017
Miss Y Gordhon Person No: 604159
Po Box 3290
Cramerview
Bryanston
2060
South Africa
TAA
Dear Miss Gordhon
Master of Pharmacy: Change of title of research
I am pleased to inform you that the following change in the title of your Dissertation for the degree of 
Master of Pharmacy has been approved:
From: Evaluating and improving the frameworks for adverse drug reaction reporting
To: Evaluating the knowledge, attitudes and practices of healthcare workers towards 
adverse drug reaction reporting in a Public Tertiary Hospital
Yours sincerely
Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences
			 123 
Appendix H: Plagiarism Detection Report (Turnitin) 
 
 
Submission author:
Assignment tit le:
Submission tit le:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnitin received your paper. Below you will f ind the receipt
inf ormation regarding your submission.
The f irst page of  your submissions is displayed below.
Yashmay Gordhon
Turnitin
YGordhonDissertation.docx
Yashmay_Gordhon_604159_YGor…
1.37M
124
25,719
156,033
19-Oct-2017 09:03AM (UTC+0200)
865357465
Copyright 2017 Turnitin. All rights reserved.
			 124 
 
			 125  
Date: 24 October 2017 
Note to Examiners:  
Please note that my student, Yashmay Gordhon (student number 604159) received a similarity 
report of 23% from Turnitin. This was due to the fact that Turnitin found an 8% similarity to a 
paper submitted to the University of Witwatersrand, which is the student’s (Yashmay Gordhon’s) 
protocol from the 24rd of March 2016. Please excuse this from the report.  
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NEELAVENI  PADAYACHEE  
______________________ 
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